WO2013138361A1 - Inhibitors of human ezh2, and methods of use thereof - Google Patents

Inhibitors of human ezh2, and methods of use thereof Download PDF

Info

Publication number
WO2013138361A1
WO2013138361A1 PCT/US2013/030565 US2013030565W WO2013138361A1 WO 2013138361 A1 WO2013138361 A1 WO 2013138361A1 US 2013030565 W US2013030565 W US 2013030565W WO 2013138361 A1 WO2013138361 A1 WO 2013138361A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
amino acid
ezh2
substitution
acid position
Prior art date
Application number
PCT/US2013/030565
Other languages
English (en)
French (fr)
Inventor
Kevin Wayne Kuntz
Sarah Kathleen KNUTSON
Timothy James Nelson WIGLE
Original Assignee
Epizyme, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/418,242 external-priority patent/US9175331B2/en
Priority to RU2014141045A priority Critical patent/RU2704445C2/ru
Priority to EP18214827.0A priority patent/EP3536314A1/en
Priority to JP2015500523A priority patent/JP6321619B2/ja
Priority to AU2013232229A priority patent/AU2013232229B2/en
Priority to KR1020217018417A priority patent/KR102453519B1/ko
Priority to HK15106526.3A priority patent/HK1205938B/en
Priority to KR1020227034498A priority patent/KR102587175B1/ko
Priority to CA2867282A priority patent/CA2867282C/en
Priority to PL13711265T priority patent/PL2825161T3/pl
Application filed by Epizyme, Inc. filed Critical Epizyme, Inc.
Priority to CN201910052279.0A priority patent/CN110420327B/zh
Priority to CN201380024734.7A priority patent/CN104540500B/zh
Priority to EP13711265.2A priority patent/EP2825161B1/en
Priority to KR1020147028560A priority patent/KR102267502B1/ko
Priority to KR1020237033924A priority patent/KR20230145531A/ko
Priority to DK13711265.2T priority patent/DK2825161T3/en
Priority to ES13711265T priority patent/ES2718900T3/es
Publication of WO2013138361A1 publication Critical patent/WO2013138361A1/en
Priority to AU2018201176A priority patent/AU2018201176A1/en
Priority to AU2019250181A priority patent/AU2019250181A1/en
Priority to AU2021202119A priority patent/AU2021202119A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
    • C12N9/1007—Methyltransferases (general) (2.1.1.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Definitions

  • PcG proteins are transcriptional repressors that maintain the "off state”
  • trxG proteins are transcriptional activators that maintain the "on state.”
  • HMTase histone methyltransferase
  • PcG and trxG proteins may participate in cellular memory through methylation of core histones.
  • Drosophila PcG proteins function in at least two distinct protein complexes, the Polycomb repressive complex 1 (PRC1) and the ESC-E(Z) complex (also known as Polycomb repressive complex 2 (PRC2)), although the compositions of the complexes may be dynamic.
  • PRC1 Polycomb repressive complex 1
  • PRC2 Polycomb repressive complex 2
  • Otte et al. (2003) Curr Opin Genet Dev 13:448-54 Studies in Drosophila (Czermin et al. ⁇ supra); Muller et al. ⁇ supra)) and mammalian cells (Cao et al. ⁇ supra); Kuzmichev et al.
  • EZH2 Enhancer of Zeste Homolog 2
  • the catalytic site of EZH2 in turn is present within a SET domain, a highly conserved sequence motif (named after Su(var)3-9, Enhancer of Zeste, Trithorax) that is found in several chromatin-associated proteins, including members of both the Trithorax group and Polycomb group.
  • SET domain is characteristic of all known histone lysine
  • the invention features a method for treating or alleviating a symptom of cancer or precancerous condition in a subject administering to a subject expressing a mutant EZH2 comprising a mutation in the substrate pocket domain as defined in SEQ ID NO: 6 a
  • the invention also features a method (or an in vitro method) of determining a responsiveness of a subject having a cancer or a precancerous condition to an EZH2 inhibitor by providing a sample from the subject; and detecting a mutation in the EZH2 substrate pocket domain as defined in SEQ ID NO: 6; and the presence of said mutation indicates the subject is responsive to the EZH2 inhibitor.
  • the invention also provides a use of an EZH2 inhibitor in a therapeutically effective amount in the manufacture of a medicament for treating or alleviating a symptom of cancer or precancerous condition in a subject expressing a mutant EZH2 comprising a mutation in the substrate pocket domain as defined in SEQ ID NO: 6.
  • the mutant EZH2 of the present invention is a mutant EZH2 polypeptide or a nucleic acid sequence encoding a mutant EZH2 polypeptide.
  • the mutant EZH2 comprises a mutation at amino acid position 677, 687, 674, 685, or 641 of SEQ ID NO: 1.
  • mutation is selected from the group consisting of a substitution of glycine (G) for the wild type residue alanine (A) at amino acid position 677 of SEQ ID NO: 1 (A677G); a substitution of valine (V) for the wild type residue alanine (A) at amino acid position 687 of SEQ ID NO: 1 (A687V); a substitution of methionine (M) for the wild type residue valine (V) at amino acid position 674 of SEQ ID NO: 1 (V674M); a substitution of histidine (H) for the wild type residue arginine (R) at amino acid position 685 of SEQ ID NO: 1 (R685H); a substitution of cysteine (C) for the wild type residue arginine (R) at amino acid position 685 of SEQ ID NO: 1 (R685C); a substitution of phenylalanine (F) for the wild type residue tyrosine (Y) at amino acid position 641 of SEQ ID NO:
  • the subject of the present invention includes any human subject who has been diagnosed with, has symptoms of, or is at risk of developing a cancer or a precancerous condition.
  • the cancer is lymphoma, leukemia or melanoma.
  • the lymphoma is non- Hodgkin lymphoma, follicular lymphoma or diffuse large B-cell lymphoma.
  • the leukemia is chronic myelogenous leukemia (CML).
  • CML chronic myelogenous leukemia
  • MDS myelodysplasia syndromes
  • Figure 2 is four graphs establishing that PRC2 complexes containing mutant EZH2 preferentially catalyze di- and tri-methylation of histone H3-K27.
  • A Methyltransferase activity of mutant and wild-type (WT) complexes on unmethylated peptide (open bars), monomethylated peptide (hashed bars), and dimethylated peptide (closed bars).
  • B Affinity for peptide substrates as judged by K 1/2 is similar across all peptide methylation states for PRC2 complexes containing wild-type (o),Y641F ( ⁇ ), Y641H ( ⁇ ), Y641N ( ⁇ ), and Y641S
  • A EZH2.
  • Figure 3B is a series of Western blot analyses of relative patterns of H3-K27 methylation status for lymphoma cell lines homozygous for WT EZH2, or heterozygous for the indicated EZH2 Y641 mutation. Panels from top to bottom depict the results of probing with antibodies specific for the following: total EZH2; H3-K27me3; H3-K27me2; H3-K27mel; and total histone H3 as loading control.
  • Figure 4 depicts selected proposed mechanisms leading to aberrantly high levels of trimethylation on histone H3-K27 in cancer. These include: a) mutation of Y641 in EZH2 resulting in a change in substrate preference from the nonmethylated to the mono- and di- methylated histone H3-K27; b) overexpression of EZH2; c) mutations in UTX that inactivate enzyme function, causing a decrease in demethylation of H3-K27me3; and d) overexpression of the PRC2 complex subunit PHF19/PCL3 that leads to increases in recruitment of the PRC2 complex to specific genes and an increase in histone H3-K27 trimethylation. In all four models the alteration leads to aberrant histone H3-K27 trimethylation in the proximal promoter regions of genes resulting in transcriptional repression of key genes in cancer.
  • Figure 5 depicts a SDS-PAGE gel showing that the expression levels of each of the five- component PRC2 complexes are similar with mutant and wild-type EZH2.
  • FIG. 6 is a pair of tables showing that mutant and wild-type (WT) PRC2 complexes display strong substrate preference for H3-K27-containing peptides.
  • Each enzyme was tested against a panel of overlapping 15-mer peptides covering all of H3 and H4. Activity was measured as velocity (CPM per minute), and the reported value represents the mean of two independent determinations for each reaction. For all the complexes the most favored peptide was H3: 16-30. WT complex had greater than 6-fold more activity against this peptide than any of the mutant complexes.
  • Figure 7 is a graph depicting inhibitory potency of S-adenosyl-L-homocysteine (SAH) against EZH2 WT and Y641 mutants of EZH2.
  • the X axis shows log concentration of SAH; theY axis shows percent inhibition.
  • Figure 8 is a graph depicting inhibitory potency of Compound 75 against EZH2 WT and Y641 mutants of EZH2.
  • the X axis shows log concentration of Compound 75; the Y axis shows percent inhibition.
  • Figure 9 depicts a Western Blot analysis of relative levels of H3-K27mel, me2 and me3 in a cell line pane, including multiple DLBCL lines expressing WT or Y641 mutatnt EZH2. Histones were extracted from the cell lines shown, fractionated by SDS-PAGE on a 4-20% gel, transferred to nitrocellulose membranes, and probed with antibodies to Histone H3, H3-K27mel, me2, or me3..
  • Figure 10 depicts an immunocytochemistry analysis of H3 and H3-K27me3 levels in a panel of WT and Y641 mutant lymphoma cell lines. Cell pellets from the indicated cell lines were fixed and embedded in paraffin. Slides were prepared and levels of H3 and H3-K27me3 were evaluated by immunocytochemistry using antibodies to histone H3, or H3-K27me3.
  • Figure 11 depicts an immunocytochemistry analysis of H3 and H3-K27me2 levels in a panel of WT and Y641 mutant lymphoma cell lines. Cell pellets from the indicated cell lines were fixed and embedded in paraffin. Slides were prepared and levels of H3 and H3-K27me2 were evaluated by immunocytochemistry using antibodies to histone H3, or H3-K27me2.
  • Figure 12 is a graph depicting the inhibition of global H3-K27me3 levels by EZH2 inhibitor treatment in Y641 mutant WSU-DLCL2 cells.
  • WSU-DLCL2 cells were treated for 4 days with the indicated concentrations of EZH2 inhibitor A or B.
  • histones were extracted, fractionated by SDS-PAGE on a 4-20% gel, transferred to nitrocellulose membranes, and probed with antibodies to Histone H3, or H3-K27me3.
  • Figure 13 is a graph showing that the EZH2 inhibitors can block proliferation of a Y641 mutant WSU-DLCL2 cells, but has little effect on non Y641 mutant OCI-LY19 cells.
  • Cells were incubated in the presence of increasing concentrations of EZH2 inhibitor A or B for eleven days. Vehicle treated (DMSO) cells were included as controls. Cell number and viability was determined using the Guava Viacount assay in a Guava EasyCyte Plus instrument. Cells were split and media and compound was replenished every 3-4 days.
  • Figure 14 is a graph showing the presence of an EZH2 (Y641) mutation and/or high H3- K27me3 and low H3-K27me2 levels predict sensitivity to EZH2 inhibitors.
  • Cell lines were maintained in the presence of increasing concentrations of one EZH2 inhibitor up to 25 ⁇ . Viable cells counts were used to derive IC 90 values after 11 days of treatment. Results are plotted with cell lines segregated according to EZH2 mutational status (A), or segregated according to H3-K27me2 and H3-K27me3 levels (B). In both plots, the line shows the average IC90 values from the indicated cell line group.
  • Figure 15 is a panel of graphs showing velocity vs. enzyme concentration measured for wild-type, A677G or A687V EZH2.
  • Biotinylated peptides representing histone H3 residues 21- 44 containing un-, mono-, di- or trimethyl lysine 27 (H3K27meO through H3K27me3) were assayed at a fixed concentration with a dilution series of the indicated EZH2 enzyme.
  • Chromatin structure is important in gene regulation and epigenetic inheritance. Post- translational modifications of histones, such as methylation are involved in the establishment and maintenance of higher-order chromatin structure.
  • Point mutations of the EZH2 gene at a single amino acid residue (e.g., Tyr641, herein referred to as Y641) of EZH2 have been reported to be linked to subsets of human B-cell lymphoma. Morin et al. (2010) Nat Genet 42(2): 181-5. In particular, Morin et al. reported that somatic mutations of tyrosine 641 (Y641F, Y641H, Y641N, and Y641S) of EZH2 were associated with follicular lymphoma (FL) and the germinal center B cell-like (GCB) subtype of diffuse large B-cell lymphoma (DLBCL).
  • FL follicular lymphoma
  • GCB germinal center B cell-like subtype of diffuse large B-cell lymphoma
  • an aspect of the present invention relates to methods for treating or alleviating a symptom of cancer or precancerous condition in a subject by administering to a subject expressing a mutant EZH2 a therapeutically effective amount of an EZH2 inhibitor.
  • the mutation of the present invention may also include a substitution of serine (S) for the wild type residue asparagine (N) at amino acid position 322 of SEQ ID NO: 3 (N322S), a substitution of glutamine (Q) for the wild type residue arginine (R) at amino acid position 288 of SEQ ID NO: 3 (R288Q), a substitution of isoleucine (I) for the wild type residue threonine (T) at amino acid position 573 of SEQ ID NO: 3 (T573I), a substitution of glutamic acid (E) for the wild type residue aspartic acid (D) at amino acid position 664 of SEQ ID NO: 3 (D664E), a substitution of glutamine (Q) for the wild type residue arginine (R) at amino acid position 458 of SEQ ID NO: 5 (R458Q), a substitution of lysine (K) for the wild type residue glutamic acid (E) at amino acid position 249 of SEQ ID NO: 3 (E2
  • EZH2 mutation is a deletion of glutamic acid (E) and leucine (L) at amino acid positions 148 and 149 of SEQ ID NO: 3, 5 or 21.
  • the mutant EZH2 may further comprise a nonsense mutation at amino acid position 733, 25, 317, 62, 553, 328, 58, 207, 123, 63, 137, or 60 of SEQ ID NO: 3, 5 or 21.
  • WT EZH2 enzyme displays greatest catalytic efficiency (kcat/K) for the zero- to mono-methylation reaction of H3-K27 and lesser efficiency for subsequent (mono- to di- and di- to tri-methylation) reactions; whereas, in stark contrast, the disease-associated Y641 mutations display very limited ability to perform the first methylation reaction but have enhanced catalytic efficiency for the subsequent reactions relative to wild-type enzyme.
  • the tyrosine (Y) residue shown underlined in SEQ ID NO: 7 is Tyr641 (Y641) in Swiss-Prot Accession No. Q15910 (SEQ ID NO: 1).
  • the SET domain of GenBank Accession No. NP_004447 (SEQ ID NO: 3) spans amino acid residues 618-731 and is identical to SEQ ID NO:6.
  • the tyrosine residue corresponding to Y641 in Swiss-Prot Accession No. Q15910 shown underlined in SEQ ID NO: 7 is Tyr646 (Y646) in GenBank Accession No. NP_004447 (SEQ ID NO: 3).
  • amino acid residue Y641 of human EZH2 is to be understood to refer to the tyrosine residue that is or corresponds to Y641 in Swiss-Prot
  • unmethylated H3-K27 refers to histone H3 with no methyl group covalently linked to the amino group of lysine 27.
  • monomethylated H3-K27 refers to histone H3 with a single methyl group covalently linked to the amino group of lysine 27.
  • Monomethylated H3-K27 is also referred to herein as H3-K27mel.
  • dimethylated H3-K27 refers to histone H3 with two methyl groups covalently linked to the amino group of lysine 27.
  • a subject expressing a mutant EZH2 of the present invention refers to a subject having a detectable amount of a mutant EZH2 polypeptide.
  • the mutant EZH2 polypeptide comprises one or more mutations in its substrate pocket domain as defined in SEQ ID NO: 6.
  • a mutant EZH2 polypeptide can be detected using any suitable method.
  • a mutant EZH2 polypeptide can be detected using an antibody that binds specifically to the mutant EZH2 polypeptide or to a peptide fragment that is characteristic of the mutant EZH2
  • an antibody is considered to bind specifically to the mutant EZH2 polypeptide or to a peptide fragment that is characteristic of the mutant EZH2 polypeptide if it binds to that mutant EZH2 polypeptide or peptide fragment thereof but not to the corresponding wild-type EZH2 polypeptide or peptide fragment thereof.
  • such antibody is considered to bind specifically to the mutant EZH2 polypeptide or to a peptide fragment that is characteristic of the mutant EZH2 polypeptide if it binds to that mutant EZH2 polypeptide or peptide fragment thereof with an affinity that is at least ca. 100-fold greater than for the corresponding wild-type EZH2 polypeptide or peptide fragment thereof.
  • such antibody is considered to bind specifically to the mutant EZH2 polypeptide or to a peptide fragment that is characteristic of the mutant EZH2 polypeptide if it binds to that mutant EZH2 polypeptide or peptide fragment thereof with an affinity that is at least ca. 1000- fold greater than for the corresponding wild-type EZH2 polypeptide or peptide fragment thereof.
  • the antibody can be used, for example, in an enzyme-linked immunosorbent assay (ELISA) or Western blot assay.
  • the antibody may be monoclonal, polyclonal, chimeric, or an antibody fragment.
  • the step of detecting the reaction product may be carried out with any suitable immunoassay.
  • the antibody is a monoclonal antibody.
  • a monoclonal antibody can be prepared according to conventional methods well known in the art. See, for example, Kohler and Milstein (1975) Nature 256 (5517):495-7.
  • a mutant EZH2 polypeptide can be detected using mass
  • a nucleic acid sequence encoding a mutant EZH2 polypeptide or a peptide fragment that is characteristic of the mutant EZH2 polypeptide can be detected using any suitable method.
  • a nucleic acid sequence encoding a mutant EZH2 polypeptide can be detected using whole-genome resequencing or target region resequencing (the latter also known as targeted resequencing) using suitably selected sources of DNA and polymerase chain reaction (PCR) primers in accordance with methods well known in the art. See, for example, Bentley (2006) Curr Opin Genet Dev. 16:545-52, and Li et al. (2009) Genome Res 19: 1124-32.
  • the method typically and generally entails the steps of genomic DNA purification, PCR amplification to amplify the region of interest, cycle sequencing, sequencing reaction cleanup, capillary electrophoresis, and data analysis.
  • High quality PCR primers to cover region of interest are designed using in silico primer design tools.
  • Cycle sequencing is a simple method in which successive rounds of denaturation, annealing, and extension in a thermal cycler result in linear amplification of extension products.
  • the products are typically terminated with a fluorescent tag that identifies the terminal nucleotide base as G, A, T, or C. Unincorporated dye terminators and salts that may compete for capillary eletrophoretic injection are removed by washing.
  • the products of the cycle sequencing reaction migrate through capillaries filled with polymer.
  • the negatively charged DNA fragments are separated by size as they move through the capillaries toward the positive electrode.
  • data collection software creates a sample file of the raw data.
  • further data analysis is performed to translate the collected color data images into the corresponding nucleotide bases.
  • the method may include the use of microarray-based targeted region genomic DNA capture and/or sequencing. Kits, reagents, and methods for selecting appropriate PCR primers and performing resequencing are
  • PCR primers may be selected so as to amplify, for example, at least a relevant portion of SEQ ID NO: 8 (above).
  • polypeptide may be detected using a Southern blot in accordance with methods well known in the art.
  • a DNA sequence encoding a mutant EZH2 polypeptide is detected using nucleic acid hybridization performed under highly stringent conditions.
  • a nucleic acid probe is selected such that its sequence is complementary to a target nucleic acid sequence that includes a codon for the mutant amino acid corresponding to a mutation of wild-type EZH2.
  • a sequence-specific probe is combined with a sample to be tested under highly stringent conditions.
  • highly stringent conditions refers to parameters with which the art is familiar. Nucleic acid hybridization parameters may be found in references that compile such methods, e.g., J. Sambrook, et al., eds., Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989, or F. M. Ausubel, et al., eds., Current Protocols in Molecular Biology, John Wiley & Sons, Inc., New York.
  • highly stringent conditions refers, for example, to hybridization at 65° C in hybridization buffer (3.5 x SSC, 0.02% Ficoll, 0.02% polyvinyl pyrrolidone, 0.02% bovine serum albumin (BSA), 2.5 mM NaH 2 P0 4 (pH 7), 0.5% SDS, 2 mM EDTA).
  • SSC is 0.15 M sodium chloride/0.015 M sodium citrate, pH 7;
  • SDS is sodium dodecyl sulphate; and
  • EDTA is ethylenediaminetetracetic acid.
  • an inhibitor of EZH2 refers, generally, to a small molecule, i.e., a molecule of molecular weight less than about 1.5 kilodaltons (kDa), which is capable of interfering with the histone methyltransferase enzymatic activity of EZH2.
  • the inhibitor of EZH2 inhibits histone methyltransferase activity of wild-type EZH2.
  • the inhibitor of EZH2 inhibits histone methyltransferase activity of the mutant EZH2.
  • the inhibitor of EZH2 inhibits histone methyltransferase activity of wild-type EZH2 and histone methyltransferase activity of the mutant EZH2. In one embodiment the inhibitor of EZH2 selectively inhibits histone
  • certain mutants of EZH2 are relatively poor catalysts for conversion of unmethylated H3-K27 to H3-K27mel and yet unexpectedly effective catalysts for conversion of H3-K27me2 to H3-K27me3.
  • Certain mutants of EZH2 (such as A687) prefer monomethyl H3-K27 substrate.
  • certain mutants of EZH2 (such as A677) show equal preference among unmethylated, monomethylated and dimethylated H3-K27.
  • wild- type EZH2 is a relatively effective catalyst for conversion of unmethylated H3-K27 to H3- K27mel and yet unexpectedly ineffective catalyst for conversion of H3-K27me2 to H3-K27me3.
  • H3-K27mel is associated with active transcription of genes that are poised for transcription
  • H3-K27me3 is associated with transcriptionally repressed genes or genes that are poised for transcription when H3-K4 trimethylation is in cis.
  • selective inhibition of histone methyltransferase activity of the mutant of EZH2 affects selective inhibition of production of the different methylated forms of H3-K27, thereby modifying transcription associated with H3-K27 methylation levels.
  • an inhibitor of EZH2 "selectively inhibits" histone methyltransferase activity of the mutant EZH2 when it inhibits histone methyltransferase activity of the mutant EZH2 more effectively than it inhibits histone methyltransferase activity of wild-type EZH2.
  • the selective inhibitor has an IC50 for the mutant EZH2 that is at least 40 percent lower than the IC50 for wild-type EZH2.
  • the selective inhibitor has an IC50 for the mutant EZH2 that is at least 50 percent lower than the IC50 for wild-type EZH2.
  • the selective inhibitor has an IC50 for the mutant EZH2 that is at least 60 percent lower than the IC50 for wild-type EZH2. In one embodiment the selective inhibitor has an IC50 for the mutant EZH2 that is at least 70 percent lower than the IC50 for wild-type EZH2. In one embodiment the selective inhibitor has an IC50 for the mutant EZH2 that is at least 80 percent lower than the IC50 for wild-type EZH2. In one embodiment the selective inhibitor has an IC50 for the mutant EZH2 that is at least 90 percent lower than the IC50 for wild-type EZH2.
  • the selective inhibitor of a mutant EZH2 exerts essentially no inhibitory effect on wild-type EZH2.
  • the inhibitor inhibits conversion of H3-K27me2 to H3-K27me3.
  • the inhibitor is said to inhibit trimethylation of H3-K27. Since conversion of H3-K27mel to H3- K27me2 precedes conversion of H3-K27me2 to H3-K27me3, an inhibitor of conversion of H3- K27mel to H3-K27me2 naturally also inhibits conversion of H3-K27me2 to H3-K27me3, i.e., it inhibits trimethylation of H3-K27. It is also possible to inhibit conversion of H3-K27me2 to H3- K27me3 without inhibition of conversion of H3-K27mel to H3-K27me2. Inhibition of this type would also result in inhibition of trimethylation of H3-K27, albeit without inhibition of dimethylation of H3-K27.
  • the inhibitor inhibits conversion of H3-K27mel to H3-K27me2 and the conversion of H3-K27me2 to H3-K27me3.
  • Such inhibitor may directly inhibit the conversion of H3-K27mel to H3-K27me2 alone.
  • such inhibitor may directly inhibit both the conversion of H3-K27mel to H3-K27me2 and the conversion of H3-K27me2 to H3-K27me3.
  • the inhibition is a measurable inhibition compared to a suitable negative control.
  • inhibition is at least 10 percent inhibition compared to a suitable negative control. That is, the rate of enzymatic activity or the amount of product with the inhibitor is less than or equal to 90 percent of the corresponding rate or amount made without the inhibitor.
  • inhibition is at least 20, 25, 30, 40, 50, 60, 70, 75, 80, 90, or 95 percent inhibition compared to a suitable negative control.
  • inhibition is at least 99 percent inhibition compared to a suitable negative control. That is, the rate of enzymatic activity or the amount of product with the inhibitor is less than or equal to 1 percent of the corresponding rate or amount made without the inhibitor.
  • the inhibitor is S-adenosyl-L-homocysteine (SAH).
  • SAH has the structural formula
  • SAH S- adenosylmethionine-dependent methyltransferases
  • the inhibitor is Compound 75
  • the invention comprises the step of performing an assay to detect a mutant of EZH2 in a sample from a subject.
  • assays of this type are described above.
  • a sample from a subject refers to any suitable sample containing cells or components of cells obtained or derived from a subject.
  • the sample includes cells suspected to express mutant EZH2, e.g., cancer cells.
  • the sample is a blood sample.
  • the sample is a biopsy sample obtained from, for example, a lymphatic tissue (e.g., lymph node) or bone marrow.
  • the sample is a biopsy sample obtained from a tissue other than or in addition to a lymphatic tissue (e.g., lymph node) or bone marrow.
  • a lymphatic tissue e.g., lymph node
  • the sample is a biopsy from a cancer, e.g., a tumor composed of cancer cells.
  • Cells in the sample can be isolated from other components of the sample.
  • peripheral blood mononuclear cells PBMCs
  • PBMCs peripheral blood mononuclear cells
  • the subject When the result of the assay on a sample from a subject indicates that a mutant EZH2 is present in the sample, the subject is said to express mutant EZH2. Indeed, in one embodiment, when the result of the assay on a sample from a subject indicates that a mutant EZH2 is present in the sample, the subject is identified as a candidate for treatment with an inhibitor of EZH2, wherein the inhibitor selectively inhibits histone methyltransferase activity of the mutant EZH2.
  • the cancer is said to express the mutant EZH2.
  • the subject is said to express the mutant EZH2.
  • Detection of dimethylated H3-K27 or trimethlated H3-K27 can be accomplished using any suitable method in the art.
  • the methylation level is detected using antibodies specific for dimethylated H3-K27 or trimethlated H3-K27.
  • the isolated tissue is formalin fixed and embedded in paraffin blocks for long term preservation. The blocks can be used to prepare slides for immunohistochemical staining or fluorescent staining with antibodies against methylated H3-K27.
  • whole cell lysates or histone extracts can be prepared from the isolated tissue sample and subsequently used for immunohistochemical staining, western blot analysis or fluorescent staining.
  • the methylation level is detected using a polypeptide or an aptamer specific for dimethylated H3-K27 or trimethlated H3-K27.
  • the methylation level is detected using mass spectrometry (MS).
  • MS mass spectrometry
  • a control dimethylated H3-K27 or a control trimethlated H3-K27 can be established from a control sample, e.g. , an adjacent non-tumor tissue isolated from the subject or a healthy tissue from a healthy subject.
  • the control methylation level of H3-K27me2 or H3- K27me3 can be established by a pathologist with known methods in the art.
  • An aspect of the invention is a method for identifying a test compound as an inhibitor of a mutant EZH2.
  • the method includes combining an isolated mutant EZH2 with a histone substrate, a methyl group donor (such as S-adenosyl methionine (SAM)), and a test compound, wherein the histone substrate comprises a form of H3-K27 selected from the group consisting of unmethylated H3-K27, monomethylated H3-K27, dimethylated H3-K27, and any combination thereof; and performing an assay to detect methylation of H3-K27 in the histone substrate, thereby identifying the test compound as an inhibitor of the mutant EZH2 when methylation of H3-K27 in the presence of the test compound is less than methylation of H3-K27 in the absence of the test compound.
  • the assay to detect methylation of H3-K27 can be selected to measure the rate of methylation, the extent of methylation, or both the rate and extent of
  • the mutant EZH2 is isolated as a PRC2 complex or functional equivalent thereof.
  • the term "isolated” means substantially separated from other components with which the complex may be found as it occurs in nature. A compound can be isolated without necessarily being purified.
  • the mutant of EZH2 is isolated as a complex of a mutant EZH2 together with EED and SUZ12.
  • the mutant of EZH2 is isolated as a complex of a mutant EZH2 together with EED, SUZ12, and RbAp48.
  • a PRC2 complex or functional equivalent thereof exhibits histone methyltransferase activity for H3-K27.
  • the complex is composed of recombinantly expressed component polypeptides, e.g., EZH2, EED, SUZ12, with or without RbAp48.
  • the isolated mutant EZH2 is combined with a histone substrate.
  • a histone substrate includes any suitable source of histone polypeptides or fragments thereof that can serve as substrate for EZH2.
  • the histone substrate includes histones isolated from a subject.
  • the histones can be isolated from cells of a subject using any suitable method; such methods are well known to persons skilled in the art and need not be further specified here. See, for example, Fang et al. (2004) Methods Enzymol 377:213-26.
  • the histone substrate is provided as nucleosomes.
  • the histone substrate is provided as avian (chicken) erythrocyte nucleosomes.
  • Histone substrate so provided may include an admixture of states of histone modification, including various states of H3-K27 methylation as judged by Western blotting with H3-K27 methylation state- specific antibodies.
  • the histone substrate may be provided as purified full-length histone H3.
  • Such purified full-length histone H3 may be provided as a homogeneous preparation in respect of states of H3-K27 methylation, or as an admixture of various states of H3-K27 methylation.
  • Homogeneous preparations of isolated histone H3 in respect of states of H3-K27 methylation may be prepared in part by passage over an
  • the methylation state of H3-K27 can be characterized as part of performing the assay.
  • the starting material histone substrate might be characterized as containing 50 percent unmethylated H3-K27, 40 percent monomethylated H3-K27, 10 percent dimethylated H3-K27, and 0 percent trimethylated H3- K27.
  • the histone substrate includes a peptide library or a suitable peptide comprising one or more amino acid sequences related to histone H3, including, in particular, a sequence that encompasses H3-K27.
  • the histone substrate is a peptide fragment that corresponds to amino acid residues 21-44 of histone H3.
  • Such peptide fragment has the amino acid sequence LATKAARK SAPATGGVKKPHRYRP (SEQ ID NO: 19).
  • the peptide library or peptide can be prepared by peptide synthesis according to techniques well known in the art and optionally modified so as to incorporate any desired degree of methylation of lysine corresponding to H3-K27.
  • such peptides can also be modified to incorporate a label, such as biotin, useful in performing downstream assays.
  • a label such as biotin
  • the label is appended to the amino (N)-terminus of the peptide(s).
  • the label is appended to the carboxy (C)-terminus of the peptide(s).
  • H3-K27 methylation- specific antibodies are available from a variety of commercial sources, including, for example, Cell Signaling Technology (Danvers, MA) and Active Motif (Carlsbad, CA).
  • test compound refers to a small organic molecule having a molecular weight of less than about 1.5 kDa.
  • a test compound is a known compound.
  • a test compound is a novel compound.
  • a test compound can be provided as part of a library of such compounds, wherein the library includes, for example, tens, hundreds, thousands, or even more compounds.
  • a library of compounds may advantageously be screened in a high throughput screening assay, for example, using arrays of test compounds and robotic manipulation in accordance with general techniques well known in the art.
  • a test compound is a compound that is a derivative of SAH or a derivative of Compound 75.
  • the source of donor methyl groups includes methyl groups that are labeled with a detectable label.
  • the detectable label in one embodiment is an isotopic label, e.g., tritium.
  • Other types of labels may include, for example, fluorescent labels.
  • Detection of formation of trimethylated H3-K27 can be accomplished using any suitable method.
  • detection of formation of trimethylated H3-K27 can be accomplished using an assay to detect incorporation of labeled methyl groups, such as described above, optionally combined with a chromatographic or other method to separate labeled products by size, e.g., polyacrylamide gel electrophoresis (PAGE), capillary electrophoresis (CE), or high pressure liquid chromatography (HPLC).
  • detection of formation of trimethylated H3-K27 can be accomplished using antibodies that are specific for trimethylated H3-K27.
  • Detection of conversion of monomethylated H3-K27 to dimethylated H3-K27 can be accomplished using any suitable method.
  • the conversion is measured using antibodies specific for monomethylated H3-K27 and dimethylated H3-K27.
  • starting amounts or concentrations of monomethylated H3-K27 and dimethylated H3-K27 may be determined using appropriate antibodies specific for monomethylated H3-K27 and dimethylated H3-K27.
  • resulting amounts or concentrations of monomethylated H3-K27 and dimethylated H3-K27 may then be determined using appropriate antibodies specific for monomethylated H3-K27 and dimethylated H3-K27.
  • the beginning and resulting amounts or concentrations of monomethylated H3-K27 and dimethylated H3-K27 can then be compared.
  • monomethylated H3-K27 and dimethylated H3-K27 can then be compared to corresponding amounts of concentrations from a negative control.
  • a negative control reaction in which no test agent is included in the assay, can be run in parallel or as a historical control. Results of such control reaction can optionally be subtracted from corresponding results of the experimental reaction prior to or in conjunction with making the comparison mentioned above.
  • H3-K27 may be further methylated in the same assay, a reduction in the amount or concentration of monomethylated H3-K27 may not appear to correspond directly to an increase in dimethylated H3-K27. In this instance, it may be presumed, however, that a reduction in the amount or concentration of monomethylated H3-K27 is, by itself, reflective of conversion of monomethylated H3-K27 to dimethylated H3-K27.
  • Detection of conversion of dimethylated H3-K27 to trimethylated H3-K27 can be accomplished using any suitable method.
  • the conversion is measured using antibodies specific for dimethylated H3-K27 and trimethylated H3-K27.
  • starting amounts or concentrations of dimethylated H3-K27 and trimethylated H3-K27 may be determined using appropriate antibodies specific for dimethylated H3-K27 and trimethylated H3- K27.
  • resulting amounts or concentrations of dimethylated H3-K27 and trimethylated H3-K27 may then be determined using appropriate antibodies specific for dimethylated H3-K27 and trimethylated H3-K27.
  • beginning and resulting amounts or concentrations of dimethylated H3-K27 and trimethylated H3-K27 can then be compared.
  • beginning and resulting amounts or concentrations of dimethylated H3-K27 and trimethylated H3-K27 can then be compared to corresponding amounts of concentrations from a negative control.
  • a negative control reaction in which no test agent is included in the assay, can be run in parallel or as a historical control. Results of such control reaction can optionally be subtracted from corresponding results of the experimental reaction prior to or in conjunction with making the comparison mentioned above.
  • a test agent is identified as an inhibitor of the mutant EZH2 when methylation of H3- K27 with the test compound is less than methylation of H3-K27 without the test compound.
  • a test agent is identified as an inhibitor of the mutant EZH2 when formation of trimethylated H3-K27 in the presence of the test compound is less than formation of
  • An aspect of the invention is a method for identifying a selective inhibitor of a mutant EZH2.
  • the method includes combining an isolated mutant EZH2 with a histone substrate, a methyl group donor (e.g., SAM), and a test compound, wherein the histone substrate comprises a form of H3-K27 selected from the group consisting of monomethylated H3-K27, dimethylated H3-K27, and a combination of monomethylated H3-K27 and
  • H3-K27 dimethylated H3-K27, thereby forming a test mixture; combining an isolated wild-type EZH2 with a histone substrate, a methyl group donor (e.g., SAM), and a test compound, wherein the histone substrate comprises a form of H3-K27 selected from the group consisting of
  • the method further includes taking into account a negative control without test compound for either or both of the test mixture and the control mixture.
  • an aspect of the invention is a method for determining a responsiveness to an EZH2 inhibitor in a subject having a cancer or a precancerous condition.
  • the method generally involves in detecting a mutation in the EZH2 substrate pocket domain as defined in SEQ ID NO: 6.
  • the mutation may be a substitution, a point mutation, a nonsense mutation, a misssense mutation, a deletion, or an insertion described above.
  • Preferred substitution amino acid mutation includes a substitution at amino acid position 677, 687, 674, 685, or 641 of SEQ ID NO: 1, such as, but is not limited to a substitution of glycine (G) for the wild type residue alanine (A) at amino acid position 677 of SEQ ID NO: 1 (A677G); a substitution of valine (V) for the wild type residue alanine (A) at amino acid position 687 of SEQ ID NO: 1 (A687V); a substitution of methionine (M) for the wild type residue valine (V) at amino acid position 674 of SEQ ID NO: 1 (V674M); a substitution of glycine (G) for the wild type residue alanine (A) at amino acid position 677 of SEQ ID NO: 1 (A677G); a substitution of valine (V) for the wild type residue alanine (A) at amino acid position 687 of SEQ ID NO: 1 (A687V); a substitution of methi
  • the subject has cancer or a cancerous condition.
  • the cancer is lymphoma, leukemia or melanoma.
  • the lymphoma is non- Hodgkin lymphoma, follicular lymphoma or diffuse large B-cell lymphoma.
  • the leukemia is chronic myelogenous leukemia (CML).
  • CML chronic myelogenous leukemia
  • MDS myelodysplasia syndromes
  • the mutant EZH2 polypeptide or the nucleic acid sequence encoding the mutant EZH2 polypeptide of the present invention comprises one or more mutations in the substrate pocket domain of EZH2 as defined in SEQ ID NO: 6. More preferably, the mutant EZH2 polypeptide or the nucleic acid sequence encoding the mutant EZH2 polypeptide of the present invention comprises a substitution at amino acid position 677, 687, 674, 685, or 641 of SEQ ID NO: 1, such as, but is not limited to a substitution of glycine (G) for the wild type residue alanine (A) at amino acid position 677 of SEQ ID NO: 1 (A677G); a substitution of valine (V) for the wild type residue alanine (A) at amino acid position 687 of SEQ ID NO: 1 (A687V); a substitution of methionine (M) for the wild type residue valine (V) at amino acid position 674 of SEQ ID NO: 1 (V67
  • One or more EZH2 antagonists can be administered alone to a human patient or in pharmaceutical compositions where they are mixed with suitable carriers or excipient(s) at doses to treat or ameliorate a disease or condition as described herein. Mixtures of these EZH2 antagonists can also be administered to the patient as a simple mixture or in suitable formulated pharmaceutical compositions.
  • one aspect of the invention relates to pharmaceutical composition comprising a therapeutically effective dose of an EZH2 antagonist, or a
  • Suitable routes of administration may, for example, include oral, rectal, or intestinal administration; parenteral delivery, including intravenous, intramuscular, intraperitoneal, subcutaneous, or intramedullary injections, as well as intrathecal, direct intraventricular, or intraocular injections; topical delivery, including eyedrop and transdermal; and intranasal and other transmucosal delivery.
  • an EZH2 antagonist in a local rather than a systemic manner, for example, via injection of the EZH2 antagonist directly into an edematous site, often in a depot or sustained release formulation.
  • an EZH2 antagonist is administered by direct injection into a tumor or lymph node. Furthermore, one may administer an EZH2 antagonist in a targeted drug delivery system, for example, in a liposome coated with cancer cell-specific antibody.
  • compositions of the present invention may be manufactured, e.g., by conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.
  • compositions for use in accordance with the present invention thus may be formulated in a conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active EZH2 antagonists into preparations which can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.
  • the agents of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiological saline buffer.
  • physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiological saline buffer.
  • penetrants are used in the formulation appropriate to the barrier to be permeated. Such penetrants are generally known in the art.
  • the EZH2 antagonists can be formulated readily by combining the active EZH2 antagonists with pharmaceutically acceptable carriers well known in the art.
  • Such carriers enable the EZH2 antagonists of the invention to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated.
  • Pharmaceutical preparations for oral use can be obtained by combining the active EZH2 antagonist with a solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores.
  • Suitable excipients include fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP).
  • disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
  • Dragee cores are provided with suitable coatings.
  • suitable coatings may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.
  • Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active EZH2 antagonist doses.
  • compositions which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol.
  • the push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers.
  • the active EZH2 antagonists may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols.
  • stabilizers may be added.
  • compositions may take the form of tablets or lozenges formulated in conventional manner.
  • the EZH2 antagonists for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebuliser, with the use of a suitable propellant, e.g.,
  • the dosage unit may be determined by providing a valve to deliver a metered amount.
  • Capsules and cartridges of e.g., gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the EZH2 antagonist and a suitable powder base such as lactose or starch.
  • the EZH2 antagonists can be formulated for parenteral administration by injection, e.g., bolus injection or continuous infusion.
  • Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative.
  • the compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
  • compositions for parenteral administration include aqueous solutions of the active EZH2 antagonists in water-soluble form. Additionally, suspensions of the active EZH2 antagonists may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the EZH2 antagonists to allow for the preparation of highly concentrated solutions.
  • the active ingredient may be in powder form for reconstitution before use with a suitable vehicle, e.g., sterile pyro gen-free water.
  • a suitable vehicle e.g., sterile pyro gen-free water.
  • the EZH2 antagonists may also be formulated in rectal compositions such as
  • suppositories or retention enemas e.g., containing conventional suppository bases, such as cocoa butter or other glycerides.
  • the EZH2 antagonists may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example, subcutaneously or intramuscularly or by intramuscular injection).
  • the EZH2 antagonists may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives (for example, as a sparingly soluble salt).
  • EZH2 antagonists may be employed.
  • Liposomes and emulsions are examples of delivery vehicles or carriers for hydrophobic drugs.
  • Certain organic solvents such as dimethysulf oxide also may be employed.
  • the EZH2 antagonists may be delivered using a sustained-release system, such as semi-permeable matrices of solid hydrophobic polymers containing the therapeutic agent.
  • Sustained-release capsules may, depending on their chemical nature, release the EZH2 antagonists for a few weeks up to over 100 days. Depending on the chemical nature and the biological stability of the therapeutic reagent, additional strategies for protein stabilization may be employed.
  • compositions may also comprise suitable solid or gel phase carriers or excipients.
  • suitable solid or gel phase carriers or excipients include but are not limited to calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers, such as polyethylene glycols.
  • a symptom of conditions and diseases such as cancers and precancerous conditions
  • the course of which can be influenced by modulating the methylation status of histones or other proteins, wherein said methylation status is mediated at least in part by the activity of EZH2.
  • Modulation of the methylation status of histones can in turn influence the level of expression of target genes activated by methylation, and/or target genes suppressed by methylation.
  • one aspect of the invention relates to a method for treating or alleviating a symptom of cancer or precancerous condition.
  • the method comprises the step of administering to a subject having a cancer or a precancerous condition and expressing a mutant EZH2 a therapeutically effective amount of an inhibitor of EZH2.
  • a mutant EZH2 polypeptide or a nucleic acid sequence encoding a mutant EZH2 polypeptide comprises a mutation in its substrate pocket domain as defined in SEQ ID NO: 6.
  • a mutant EZH2 polypeptide or a nucleic acid sequence encoding a mutant EZH2 polypeptide comprises a substitution mutation at amino acid position 677, 687, 674, 685, or 641 of SEQ ID NO: 1, such as, but is not limited to a substitution of glycine (G) for the wild type residue alanine (A) at amino acid position 677 of SEQ ID NO: 1 (A677G); a substitution of valine (V) for the wild type residue alanine (A) at amino acid position 687 of SEQ ID NO: 1 (A687V); a substitution of methionine (M) for the wild type residue valine (V) at amino acid position 674 of SEQ ID NO: 1 (V674M); a substitution of histidine (H) for the wild type residue arginine (R) at amino acid position 685 of SEQ ID NO: 1 (R685H); a substitution of cysteine (C) for the wild type residue arg
  • the inhibitor inhibits histone methyltransferase activity of the mutant EZH2. In one embodiment the inhibitor selectively inhibits histone methyltransferase activity of the mutant EZH2.
  • the cancer is a lymphoma.
  • the cancer is a non- Hodgkin lymphoma, a follicular lymphoma or a diffuse large B-cell lymphoma (DLBCL).
  • the cancer is leukemia (such as CML) or melanoma.
  • the precancerous condition includes, but is not limited to, myelodysplasia syndromes (MDS, formerly known as preleukemia).
  • Diseases such as cancers and neurological disease can be treated by administration of modulators of protein (e.g., histone) methylation, e.g., modulators of histone methyltransferase, or histone demethylase enzyme activity.
  • histone methylation has been reported to be involved in aberrant expression of certain genes in cancers, and in silencing of neuronal genes in non- neuronal cells.
  • Modulators described herein can be used to treat such diseases, i.e., to inhibit methylation of histones in affected cells.
  • a method for treating cancer or a precancerous condition with a mutant EZH2 in a subject comprises administering to the subject in need thereof a therapeutically effective amount of a compound that inhibits methylation or restores methylation to roughly its level in counterpart normal cells.
  • a method for treating cancer or a precancerous condition in a subject comprises administering to the subject in need thereof a therapeutically effective amount of a compound that inhibits conversion of unmethylated H3-K27 to monomethylated H3-K27 (H3-K27mel).
  • a method for treating cancer or a precancerous condition in a subject comprises administering to the subject in need thereof a therapeutically effective amount of a compound that inhibits conversion of monomethylated H3-K27 (H3-K27mel) to dimethylated H3-K27 (H3-K27me2).
  • a method for treating cancer or a precancerous condition in a subject comprises administering to the subject in need thereof a therapeutically effective amount of a compound that inhibits conversion of H3-K27me2 to trimethylated H3-K27 (H3-K27me3).
  • a method for treating cancer or a precancerous condition in a subject comprises administering to the subject in need thereof a therapeutically effective amount of a compound that inhibits both conversion of H3-K27mel to H3-K27me2 and conversion of H3- K27me2 to H3-K27me3.
  • disease-specific increase in methylation can occur at chromatin in key genomic loci in the absence of a global increase in cellular levels of histone or protein methylation.
  • Modulators of methylation can be used for modulating cell proliferation, generally. For example, in some cases excessive proliferation may be reduced with agents that decrease methylation, whereas insufficient proliferation may be stimulated with agents that increase methylation. Accordingly, diseases that may be treated include hyperproliferative diseases, such as benign cell growth and malignant cell growth (cancer).
  • cancer malignant cell growth
  • Exemplary cancers that may be treated include lymphomas, including non-Hodgkin lymphoma, follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL); melanoma; and leukemia, including CML.
  • Exemplary precancerous condition includes myelodisplastic syndrome (MDS; formerly known as preleukemia).
  • cancers include Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia;
  • Germ Cell Tumor Extracranial; Germ Cell Tumor,
  • Germ Cell Tumor Ovarian; Gestational Trophoblastic Tumor; Glioma; Glioma, Childhood Brain Stem; Glioma, Childhood Cerebral Astrocytoma; Glioma, Childhood Visual Pathway and Hypothalamic; Hairy Cell Leukemia; Head and Neck Cancer; Hepatocellular (Liver) Cancer, Adult (Primary); Hepatocellular (Liver) Cancer, Childhood (Primary);
  • Hodgkin's Lymphoma Hodgkin's Lymphoma During Pregnancy; Hypopharyngeal Cancer; Hypothalamic and Visual Pathway Glioma; Intraocular Melanoma; Islet Cell Carcinoma
  • Lymphoma Primary Central Nervous System; Macroglobulinemia, Waldenstrom's; Malignant Fibrous Histiocytoma of Bone/Osteosarcoma; Medulloblastoma; Melanoma; Merkel Cell Carcinoma; Mesothelioma; Mesothelioma, Adult Malignant; Metastatic Squamous Neck Cancer with Occult Primary; Multiple Endocrine Neoplasia Syndrome; Multiple Myeloma; Multiple Myeloma/Plasma Cell Neoplasm Mycosis Fungoides; Myelodysplasia Syndromes;
  • Myelodysplastic/Myeloproliferative Diseases Myeloid Leukemia, Adult Acute; Myeloid Leukemia, Childhood Acute; Myeloproliferative Disorders, Chronic; Nasal Cavity and Paranasal Sinus Cancer; Nasopharyngeal Cancer; Neuroblastoma; Non-Hodgkin's Lymphoma; Non- Hodgkin's Lymphoma During Pregnancy; Oral Cancer; Oral Cavity Cancer, Lip and;
  • Oropharyngeal Cancer Osteosarcoma/Malignant Fibrous Histiocytoma of Bone; Ovarian Cancer; Ovarian Epithelial Cancer; Ovarian Low Malignant Potential Tumor; Pancreatic Cancer; Pancreatic Cancer, Islet Cell; Paranasal Sinus and Nasal Cavity Cancer; Parathyroid Cancer; Penile Cancer; Pheochromocytoma; Pineoblastoma and Supratentorial Primitive
  • neurologic diseases that may be treated include epilepsy, schizophrenia, bipolar disorder or other psychological and/or psychiatric disorders, neuropathies, skeletal muscle atrophy, and neurodegenerative diseases, e.g., a neurodegenerative disease.
  • exemplary neurodegenerative diseases include: Alzheimer's, Amyotrophic Lateral Sclerosis (ALS), and Parkinson's disease.
  • Another class of neurodegenerative diseases includes diseases caused at least in part by aggregation of poly-glutamine. Diseases of this class include: Huntington's Diseases, Spinalbulbar Muscular Atrophy (SBMA or Kennedy's Disease),
  • Lysodren Matulane®, mithracin, Mitomycin-C, Myleran®, Navelbine®, Neutrexin®, nilotinib, Nipent®, Nitrogen Mustard, Novantrone®, Oncaspar®, Panretin®, Paraplatin®, Platinol®, prolifeprospan 20 with carmustine implant, Sandostatin®, Targretin®, Tasigna®, Taxotere®, Temodar®, TESPA, Trisenox®, Valstar®, Velban®, VidazaTM, vincristine sulfate, VM 26, Xeloda® and Zanosar®); biologies (such as Alpha Interferon, Bacillus Calmette-Guerin, Bexxar®, Campath®, Ergamisol®, Erlotinib, Herceptin®, Interleukin-2, Iressa®, lenalidomide, Mylotarg®, Ontak®, Pegasys®, Revlim
  • Y is H or halo
  • any aryl or heteroaryl moiety of said aryl, heteroaryl, aryl(C 1 -C 4 )alkyl, or heteroaryl(C 1 -C 4 )alkyl is optionally substituted by 1, 2 or 3 groups independently selected from the group consisting of halo, (Ci-C 6 )alkyl, (C 3 -Cg)cycloalkyl, (C 5 - C 8 )cycloalkenyl, (Ci-C 6 )haloalk l, cyano, -COR a , -C0 2 R a , -CONR a R b ,-SR a , -SOR a ., -S0 2 R a , -S0 2 NR a R b , nitro, -NR a R b , -NR a C(0)R b ,-NR a C(0)NR a R b , -NR a C(0)OR a R
  • R a and R b are each independently hydrogen, (Ci-Cg)alkyl, (C 2 -Cg)alkenyl, (C 2 - Cg)alkynyl, (C 3 -Cg)cycloalkyl, (Cs-Cg)cycloalkenyl, (C 6 -C 1 o)bicycloalkyl, heterocycloalkyl, aryl, or heteroaryl, wherein said (Ci-Cg)alkyl, (C 2 -Cg)alkenyl, (C 2 -Cg)alkynyl, cycloalkyl,
  • heterocycloalkyl aryl, or heteroaryl ring
  • X and Z are selected from the group consisting of (C 1 -Cg)alkyl, (C 3 -Cg)cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -NR a R b , and -OR a ;
  • Y is H or F
  • heterocycloalkyl aryl, and heteroaryl
  • R is hydrogen, (Ci-Cg)alkyl, trifluoromethyl, alkoxy, or halo, in which said (Ci-Cg)alkyl is optionally substituted with one to two groups selected from amino and (C 1 -C 3 )alkylamino;
  • R is hydrogen, (Ci-C 3 )alkyl, or alkoxy
  • R is selected from the group consisting of hydrogen, (Ci-Cg)alkyl, cyano,
  • R 6 is selected from the group consisting of hydrogen, halo, cyano, trifluoromethyl, amino, (C 1 -C 8 )aLkyl, (C3-C 8 )cycloalkyl;, aryl, heteroaryl, acylamino; (C 2 -C 8 )alkynyl,
  • any (C 1 -Cg)alkyl, (C 3 -Cg)cycloalkyl, (C 2 -Cg)alkynyl, arylalkynyl, heteroarylalkynyl group is optionally substituted by 1, 2 or 3 groups independently selected from -0(C 1 -C 6 )alkyl(R c ) 1 _ 2 , -S(C 1 -C 6 )alkyl(R c ) 1 _ 2 , -(Ci- C 6 )alkyl(R c )i_ 2 , -(Ci-C 8 )alkyl-heterocycloalkyl, (C 3 -C 8 )cycloalkyl- heterocycloalkyl, halo, (C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl, (C 5 -C 8 )cycloalkenyl, (Q- C 6 )halo
  • -S0 2 NR a R b nitro, -NR a R b , -NR a C(0)R b , -NR a C(0)NR a R b , -NR a C(0)OR a , -NR a S0 2 R b , - NR a S0 2 NR a R b , -OR a , -OC(0)R a , -OC(0)NR a R b , heterocycloalkyl, aryl, heteroaryl, aryl(C 1 -C 4 )alkyl, and heteroaryl(C 1 -C 4 )alkyl;
  • R a and R b are each independently hydrogen, (CrC ⁇ alkyl, (C 2 -C8)alkenyl, (C 2 - C8)alkynyl, (C 3 -C 8 )cycloalkyl, (C 5 -C 8 )cycloalkenyl, (C 6 -C 1 o)bicycloalkyl, heterocycloalkyl, aryl, or heteroaryl, wherein said (C 1 -Cs)alkyl, (C 2 -C 8 )alkenyl, (C 2 -C 8 )alkynyl, cycloalkyl,
  • cycloalkenyl, bicycloalkyl, heterocycloalkyl ,aryl or heteroaryl group is optionally substituted by 1, 2 or 3 groups independently selected from halo, hydroxyl, (Ci-C 4 )alkoxy, amino, (Q- C 4 )alkylamino, ((C 1 -C 4 )alkyl)((C 1 -C 4 )alkyl)amino, -C0 2 H, -C0 2 (C 1 -C 4 )alkyl, -CONH 2 , - CONH(Ci-C 4 )alkyl, -CON((Ci-C 4 )alkyl)((Ci-C 4 )alkyl), -S0 2 (Ci-C 4 )alkyl, -S0 2 NH 2 ,- S0 2 NH(Ci-C 4 )alkyl, and
  • R a and R b taken together with the nitrogen to which they are attached represent a 5-8 membered saturated or unsaturated ring, optionally containing an additional heteroatom selected from oxygen, nitrogen, and sulfur, wherein said ring is optionally substituted by 1, 2 or 3 groups independently selected from (Ci-C 4 )alkyl, (C 1 -C 4 )haloalkyl, amino, (C 1 -C 4 )alkylamino, ((Q- C 4 )alkyl)((C 1 -C 4 )alkyl)amino, hydroxyl, oxo, (Ci-C 4 )alkoxy, and (C 1 -C 4 )alkoxy(C 1 -C 4 )alkyl, wherein said ring is optionally fused to a (C 3 -C 8 )cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring;
  • R a and R b taken together with the nitrogen to which they are attached represent a 6- to 10-membered bridged bicyclic ring system optionally fused to a (C 3 -Cg)cycloalkyl,
  • A is O NH, or S; B is CH or N, and C is hydrogen or Ci-C 8 alkyl; or
  • J is O, S or CO;
  • M is CH or N; and L/(5) is hydrogen, halo, amino, cyano, (Ci-C 8 )alkyl, (C 3 -C 8 )cycloalkyl, -COR a , -C0 2 R a , -CONR a R b , -CONR a NR a R b , -S0 2 R a , -S0 2 NR a R b , -NR a R b , -NR a C(0)R b ,-NR a S0 2 R b ,
  • any (C 1 -Cg)alkyl or (C 3 -Cg)cycloalkyl group is optionally substituted by 1, 2 or 3 groups independently selected from (Ci-C 6 )alkyl, (C 3 -C 8 )cycloalkyl, (C 5 - C 8 )cycloalkenyl, (CrCe ⁇ aloalkyl, cyano, -COR a , -C0 2 R a , -CONR a R b , -SR a , -SOR a , -S0 2 R a , -S0 2 NR a R b , nitro, -NR a R b , -NR a C(0)R b , -NR a C(0)NR a R b , -NR a C(0)OR a , -NR a S0 2 R b , -NR a S0 2 NR a R b , -OR
  • L/(6) is NH or CH 2 ;
  • any (C Cs kyl, (C 3 -C8)cycloalkyl, or heterocycloalkyl group is optionally substituted by 1, 2 or 3 groups independently selected from (C 1 -C 6 )alkyl, (C 3 - C 8 )cycloalkyl, (C 5 -C 8 )cycloalkenyl, (Ci-C 6 )haloalkyl, cyano, -COR a , -C0 2 R a ,
  • P is CH 2 , NH, O, or S;
  • Q/(8) is CH or N; and
  • n is 0-2; or
  • S/(9) and T/(9) is C, or S/(9) is C and 17(9) is N, or S/(9) is N and 17(9) is C;
  • R is hydrogen, amino, methyl, trifluoromethyl, or halo
  • U is hydrogen, halo, amino, cyano, nitro, trifluoromethyl, (C Cs kyl, (C 3 -
  • any (C C 8 )alkyl or (C 3 -C 8 )cycloalkyl group is optionally substituted by 3 groups independently selected from (Ci-C6)alkyl, (C 3 -Cg)cycloalkyl, (C 5 -
  • X and Z are selected independently from the group consisting of (C C 8 )alkyl, (C 3 - Cg)cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -NR a R b , and -OR a ;
  • Y is H
  • R 1 is (C C 8 )alkyl, (C 3 -C 8 )cycloalkyl, or heterocycloalkyl;
  • R is hydrogen, (CrC 3 )alkyl, or halo, in which said (CrC 3 )alkyl is optionally substituted with one to two groups selected from amino and (C 1 -C 3 )alkylamino;
  • R is hydrogen, (Ci-C 3 )alkyl, or alkoxy; R is hydrogen, (C 1 -C 8 )alkyl or halo;
  • R 6 is hydrogen, halo, cyano, trifluoromethyl, amino, (CrC ⁇ alkyl, (C 3 -C 8 )cycloalkyl, aryl, heteroaryl, acylamino; (C 2 -C 8 )alkynyl, arylalkynyl, heteroarylalkynyl, -S0 2 R a , -S0 2 NR a R b , or
  • any (CrC ⁇ alkyl, (C 3 -C 8 )cycloalkyl, (C 2 -C 8 )alkynyl, arylalkynyl, or heteroarylalkynyl group is optionally substituted by 1, 2 or 3 groups independently selected from halo, (C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl, (C 5 -C 8 )cycloalkenyl, (C - C 6 )haloalkyl, cyano, -COR a , -C0 2 R a , -CONR a R b , -SR a , -SOR a , -S0 2 R a , - S0 2 NR a R b , nitro, -NR a R b , -NR a C(0)R b , -NR a C(0)NR a R b , -NR a C(0)
  • R a and R b are each independently hydrogen, (CrC ⁇ alkyl, (C 2 -C 8 )alkenyl, (C 2 - C 8 )alkynyl, (C 3 -C 8 )cycloalkyl, (C 5 -C 8 )cycloalkenyl, (C 6 -C 1 o)bicycloalkyl, heterocycloalkyl, aryl, or heteroaryl, wherein said (C 1 -Cs)alkyl, (C 2 -C 8 )alkenyl, (C 2 -C 8 )alkynyl, cycloalkyl,
  • cycloalkenyl, bicycloalkyl, heterocycloalkyl ,aryl or heteroaryl group is optionally substituted by 1, 2 or 3 groups independently selected from halo, hydroxyl, (Ci-C 4 )alkoxy, amino, (Cr
  • R a and R b taken together with the nitrogen to which they are attached represent a 5-8 membered saturated or unsaturated ring, optionally containing an additional heteroatom selected from oxygen, nitrogen, and sulfur, wherein said ring is optionally substituted by 1, 2 or 3 groups independently selected from (Ci-C 4 )alkyl, (C 1 -C 4 )haloalkyl, amino, (C 1 -C 4 )alkylamino, ((Q- C 4 )alkyl)((C 1 -C 4 )alkyl)amino, hydroxyl, oxo, (Ci-C 4 )alkoxy, and (C 1 -C 4 )alkoxy(C 1 -C 4 )alkyl, wherein said ring is optionally fused to a (C 3 -C 8 )cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring;
  • R a and R b taken together with the nitrogen to which they are attached represent a 6- to 10-membered bridged bicyclic ring system optionally fused to a (C 3 -C 8 )cycloalkyl,
  • A is O, NH, or S; B is CH or N, and C is hydrogen or Q-Cg alkyl; or
  • D is N or C optionally substituted by hydrogen or C Cg alkyl
  • E is NH or CH 2 ;
  • F is O or CO; and
  • G is NH or CH 2 ; or
  • J is O, S or CO;
  • Q is CH or N
  • M is CH or N
  • L/(5) is hydrogen, halo, amino, cyano, (Ci-C 8 )alkyl, (C 3 -C 8 )cycloalkyl, -COR a , -C0 2 R a , -CONR a R b , -CONR a NR a R b , -S0 2 R a , -S0 2 NR a R b , -NR a R b , -NR a C(0)R b ,-NR a S0 2 R b ,
  • any (Ci-C8)alkyl, (C 3 -C 8 )cycloalkyl, group is optionally substituted by 1,2 or 3 groups independently selected from (Ci-C 6 )alkyl, (C 3 -C 8 )cycloalkyl, (C 5 - C 8 )cycloalkenyl, (Ci-C 6 )haloalkyl, cyano, -COR a , -C0 2 R a , -CONR a R b , -SR a , -SOR a , - S0 2 R a , -S0 2 NR a R b , nitro, -NR a R b , -NR a C(0)R b , -NR a C(0)NR a R b , -NR a C(0)OR a , NR a S0 2 R b , -NR a S0 2 NR a R b , -NR
  • R a and R b are defined as above;
  • L/ 6 is NH or CH 2 ;
  • M/(7) is hydrogen, halo, amino, cyano, (C 1 -Cg)alkyl, (C 3 -Cg)cycloalkyl, heterocycloalkyl, -COR a , -C0 2 R a , -CONR a R b , -CONR a NR a R b , -S0 2 R a , -S0 2 NR a R b , -NR a R b , -NR a C(0)R b ,-NR a S0 2 R b , -NR a S0 2 NR b , -NR a S0 2 NR a R b , -NR a S0 2 NR a R b , -NR a NR a R b , -NR a NR a C(0)R b , -NR a NR a C(0)NR b , or -OR a ,
  • any (C 1 -Cg)alkyl, (C 3 -Cg)cycloalkyl, heterocycloalkyl group is optionally substituted by 1, 2 or 3 groups independently selected from (C 1 -C 6 )alkyl, (C 3 - C 8 )cycloalkyl, (C 5 -Cg)cycloalkenyl, (CrCe ⁇ aloalkyl, cyano, -COR a , -C0 2 R a , - CONR a R b , -SR a , -SOR a , -S0 2 R a , -S0 2 NR a R b , nitro, -NR a R b , -NR a C(0)R b ,
  • P is CH 2 , NH, O, or S;
  • Q/(8) is CH or N; and
  • n is 0-2; or
  • S/(9) and T/(9) is C, or S/(9) is C and 17(9) is N, or S/(9) is N and 17(9) is C;
  • R is hydrogen, amino, methyl, trifluoromethyl, halo
  • U is hydrogen, halo, amino, cyano, nitro, trifluoromethyl, (C 1 -Cg)alkyl, (C 3 - C 8 )cycloalkyl, -COR a , -C0 2 R a , -CONR a R b , -S0 2 R a , -S0 2 NR a R b , -NR a R b , -NR a C(0)R b ,- NR a S0 2 R b ,
  • any (C 1 -Cg)alkyl, or (C 3 -Cg)cycloalkyl group is optionally substituted by 1, 2 or 3 groups independently selected from (CrC 6 )alkyl, (C 3 -C8)cycloalkyl, (C 5 - C 8 )cycloalkenyl, (CrCe ⁇ aloalkyl, cyano, -COR a , -C0 2 R a ,-CONR a R b ,-SOR a ,-S0 2 R a , -S0 2 NR a R b , nitro, -NR a R b , -NR a C(0)R b , -NR a C(0)NR a R b , -NR a C(0)OR a , -NR a S0 2 R b , -NR a S02NR a R b , -OR a , -OC(0)R a , and
  • X is methyl, ethyl, n-propyl, isopropyl , cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, trifluoromethyl, tetrahydropyran, hydroxymethyl, methoxymethyl, or benzyl;
  • Y is H
  • Z is methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, or benzyl;
  • R is isopropyl, tert-butyl, cyclobutyl, cyclopentyl, cyclohexyl, (1- methylethyl)cyclopropyl, 1 , 1 -dioxo-tetrahydrothiophene-3-yl, 1 -Me-piperidin-4-yl,
  • R is hydrogen, (C 1 -C 3 )alkyl, or halo, in which said (C 1 -C 3 )alkyl is optionally substituted with one to two groups selected from amino and (C 1 -C 3 )alkylamino;
  • R is hydrogen, (Ci-C 3 )alkyl, or alkoxy
  • R is H, methyl, or Br
  • R 6 is methyl, bis(l,l-dimethylethyl), bis(l-methylethyl), cyclopropyl, propyl,
  • the compounds suitable for use in the method of this invention also include compounds of Formula (II):
  • Xi is N or CR n ;
  • X 2 is N or CR 13 ;
  • Zi is NR 7 R 8 , OR 7 , SR 7 , or CR 7 R 8 R 14 ;
  • each of Ri, R 5 , R9, and Rio is H or Ci-C 6 alkyl optionally substituted with one or more substituents selected from the group consisting of halo, hydroxyl, COOH, C(0)0- Ci-C 6 alkyl, cyano, Ci-C 6 alkoxyl, amino, mono-Ci-C 6 alkylamino, di-Ci-C 6 alkylamino, C 3 -Cg cycloalkyl, C 6 -Cio aryl, 4 to 12-membered heterocycloalkyl, and 5- or 6-membered heteroaryl; each of R 2 , R 3 , and R 4 , independently, is -Q 1 -T 1 , in which Qi is a bond or Ci-C 3 alkyl linker optionally substituted with halo, cyano, hydroxyl or Ci-C 6 alkoxy, and Ti is H, halo, hydroxyl, COOH, cyano, or R sl , in which
  • heterocycloalkyl and 5- or 6-membered heteroaryl
  • R 6 is C 6 -C 10 aryl or 5- or 6-membered heteroaryl, each of which is optionally substituted with one or more -Q 2 -T 2 , wherein Q 2 is a bond or Ci-C 3 alkyl linker optionally substituted with halo, cyano, hydroxyl or Ci-C 6 alkoxy, and T 2 is H, halo, cyano, -OR a , -NR a R b , -(NR a R b R c ) + A , -C(0)R a , -C(0)OR a , -C(0)NR a R b , -NR b C(0)R a , -NR b C(0)OR a , -S(0) 2 R a , -S(0) 2 NR a R b , or R S2 , in which each of R a , R b , and R c , independently is H or Rs 3 , A is a pharmaceutical
  • 5- or 6-membered ring optionally containing 1-4 heteroatoms selected from N, O and S and optionally substituted with one or more substituents selected from the group consisting of halo, hydroxyl, COOH, C(0)0-Ci-C 6 alkyl, cyano, CrC 6 alkoxyl, amino, mono-Q-Ce alkylamino, di- C -C alkylamino, C 3 -C 8 cycloalkyl, C 6 -Cio aryl, 4 to 12-membered heterocycloalkyl, and 5- or
  • 6- membered heteroaryl provided that -Q 2 -T 2 is not H;
  • R 7 is -Q4-T4, in which Q 4 is a bond, CrC 4 alkyl linker, or C 2 -C 4 alkenyl linker, each linker optionally substituted with halo, cyano, hydroxyl or CrC 6 alkoxy, and T 4 is H, halo, cyano, NR f R g , -OR f , -C(0)R f , -C(0)OR f , -C(0)NR f R g , -C(0)NR f OR g , -NR f C(0)R g , -S(0) 2 R f , or Rs 4 , in which each of R f and R g , independently is H or R S 5, each of R S4 and R S 5, independently is CrC 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, C 6 -C 10 aryl, 4 to
  • each of R 8 , R 11 ; R12, and R 13 independently, is H, halo, hydroxyl, COOH, cyano, R s6 , OR s6 , or COORse, in which R s6 is C C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, 4 to 12-membered heterocycloalkyl, amino, mono-Ci-C 6 alkylamino, or di-C C 6 alkylamino, and Rs 6 is optionally substituted with one or more substituents selected from the group consisting of halo, hydroxyl, COOH, C(0)0-C 1 -C 6 alkyl, cyano, C -C alkoxyl, amino, mono-C Ce alkylamino, and di-C ⁇ Ce alkylamino; or R 7 and R 8 , together with the N atom to which they are attached, form a 4 to
  • R 14 is absent, H, or Q-C 6 alkyl optionally substituted with one or more substituents selected from the group consisting of halo, hydroxyl, COOH, C(0)0-C 1 -C 6 alkyl, cyano, Ci-C 6 alkoxyl, amino, mono-Q-Ce alkylamino, di-Q-Ce alkylamino, C 3 -Cg cycloalkyl, C 6 -C 10 aryl, 4 to 12-membered heterocycloalkyl, and 5- or 6-membered heteroaryl.
  • substituents selected from the group consisting of halo, hydroxyl, COOH, C(0)0-C 1 -C 6 alkyl, cyano, Ci-C 6 alkoxyl, amino, mono-Q-Ce alkylamino, di-Q-Ce alkylamino, C 3 -Cg cycloalkyl, C 6 -C 10 aryl, 4 to 12-membered heterocycloalkyl,
  • One subset of the compounds of Formula (II) includes those of Formula (Ila):
  • Another subset of the compounds of Formula (II) includes those of Formula (lib), (lie), or (lid):
  • the compounds of Formulae (II), (Ila), (lib), (lie), and (lid) can include one or more of the following features:
  • X 1 is CRn and X 2 is CR 13 .
  • CRn is CRn and X 2 is N.
  • N is N and X 2 is CR 13 .
  • X 1 is N and X 2 is N.
  • Z ⁇ is NR 7 Rg.
  • ⁇ is CR 7 R 8 Ri 4 .
  • ⁇ is OR 7 .
  • ⁇ is SR 7.
  • R 6 is phenyl substituted with one or more -Q 2 -T 2 .
  • R 6 is 5 to 6-membered heteroaryl containing 1-3 additional heteroatoms selected from N, O, and S and optionally substituted with one or more -Q 2 -T 2 .
  • R 6 is pyridinyl, pyrazolyl, pyrimidinyl, quinolinyl, tetrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, furyl, or thienyl, each of which is optionally substituted with one or more -Q 2 -T 2 .
  • Q 2 is a bond
  • Q 2 is an unsubstituted Q-C 3 alkyl linker.
  • T 2 is CrC 6 alkyl or C6-Cio aryl, each optionally substituted with one or more -Q 3 -T 3 .
  • T 2 is an unsubstituted substituted straight chain C -C or branched C 3 -C 6 alkyl, including but not limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, t-butyl, n-pentyl, s-pentyl and n-hexyl.
  • T 2 is phenyl
  • T 2 is halo (e.g. , fluorine, chlorine, bromine, and iodine).
  • T 2 is 4 to 7-membered heterocycloalkyl (e.g., azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, triazolidinyl, tetrahyrofuranyl, piperidinyl, 1,2,3,6-tetrahydropyridinyl, piperazinyl, tetrahydro-2H-pyranyl, 3,6-dihydro-2H-pyranyl, tetrahydro-2H-thiopyran, morpholinyl, 1,4-diazepanyl, 1,4-oxazepanyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl, 2,5-diazabicyclo[2.2.1]heptanyl, and the like) optionally substituted with one or
  • T 2 is -OR a , -NR a R b , -(NR a R b R c ) + A ,-C(0)R a , -C(0)OR a ,
  • T 2 is -NR a R b or -C(0)NR a R b , in which each of R a and R b , independently is H or CrC 6 alkyl, or R a and R b , together with the N atom to which they are attached, form a 4 to 7-membered heterocycloalkyl ring having 0 or 1 additional heteroatom, the C -C alkyl and the 4 to 7-membered heterocycloalkyl ring being optionally substituted with one or more -Q3-T3.
  • Q 2 is Q-C 3 alkyl linker optionally substituted with halo or hydroxyl.
  • Q 2 is a bond or methyl linker and T 2 is H, halo, -OR a , -NR a R b ,
  • each of R a , R b , and R c independently is H or C -C alkyl optionally substituted with one or more -Q3-T3.
  • R a , R b , and R c is H.
  • R a and R b together with the N atom to which they are attached, form a 4 to 7-membered heterocycloalkyl ring having 0 or 1 additional heteroatoms to the N atom (e.g., azetidinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, triazolidinyl, piperidinyl, 1,2,3,6-tetrahydropyridinyl, piperazinyl, morpholinyl, 1,4-diazepanyl, 1,4- oxazepanyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl, 2,5-diazabicyclo[2.2.1]heptanyl, and the like) and the ring is optionally substituted with one or more -
  • -Q3-T3 is oxo
  • T 2 is 4 to 7-membered heterocycloalkyl or C 3 -C 8 cycloalkyl and one or
  • (3 ⁇ 4 is a bond or unsubstituted or substituted Q-C 3 alkyl linker.
  • T 3 is H, halo, 4 to 7-membered heterocycloalkyl, Q-C 3 alkyl, OR d , COOR d ,-S(0) 2 R d , or -NR d R e .
  • R d and R e are H.
  • R 7 is -C(0)R f .
  • R 7 is -C(0)R f , in which R f is C 3 -C 8 cycloalkyl.
  • R 7 is C6-Cio aryl substituted with one or more -Q5-T5.
  • R 7 is phenyl optionally substituted with one or more -Q5-T5.
  • R 7 is CrC 6 alkyl optionally substituted with one or more -Q5-T5.
  • R 7 is C 3 -C 8 cycloalkyl optionally substituted with one or more
  • R 7 is 4 to 7-membered heterocycloalkyl (e.g., azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, triazolidinyl, tetrahyrofuranyl, piperidinyl, 1,2,3,6-tetrahydropyridinyl, piperazinyl, tetrahydro-2H-pyranyl, 3,6-dihydro-2H-pyranyl, tetrahydro-2H-thiopyran, and morpholinyl, and the like) optionally substituted with one or more -Q5-T5.
  • heterocycloalkyl e.g., azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, imidazolidiny
  • R 7 is 5 to 6-membered heterocycloalkyl optionally substituted with one or
  • R 7 is isopropyl
  • R 7 is pyrrolidinyl, piperidinyl, tetrahydropyran, tetrahydro-2H-thiopyranyl, cyclopentyl, or cyclohexyl, cycloheptyl, each optionally substituted with one or more -Q5-T5.
  • R 7 is cyclopentyl cyclohexyl or tetrahydro-2H-thiopyranyl, each optionally substituted with one or more -Q 5 -T5.
  • one or more -Q 5 -T5 are oxo.
  • R 7 is l-oxide-tetrahydro-2H-thiopyranyl or l, l-dioxide-tetrahydro-2H- thiopyranyl.
  • Q 5 is a bond and T5 is amino, mono-Ci-C 6 alkylamino, di-C C 6 alkylamino.
  • (3 ⁇ 4 is NHC(O) and T5 is C -C alkyl or C -C alkoxy.
  • T 4 is 4 to 7-membered heterocycloalkyl or C 3 -C 8 cycloalkyl and one or
  • T5 is H, halo, C -C alkyl, C -C alkoxyl, C 3 -C 8 cycloalkyl, C 6 -Cio aryl, or 4 to 7-membered heterocycloalkyl.
  • Q 5 is a bond and T5 is C C 6 alkyl, C 3 -C 8 cycloalkyl, or 4 to 7-membered heterocyclo alkyl .
  • Q 5 is CO, S(0) 2 , or NHC(O); and T 5 is Ci-Ce alkyl, Ci-Ce alkoxyl, C 3 -C 8 cycloalkyl, or 4 to 7-membered heterocycloalkyl.
  • T5 is CrC 6 alkyl or CrC 6 alkoxyl, each optionally substituted with halo, hydroxyl, cyano, CrC 6 alkoxyl, amino, mono-Ci-C 6 alkylamino, di-CrC 6 alkylamino, or C Cs cycloalkyl.
  • Q 5 is Q-C 3 alkyl linker and T5 is H or C 6 -C 10 aryl.
  • Q 5 is C C ? alkyl linker and T5 is C3-C 8 cycloalkyl, 4 to 7-membered heterocycloalkyl, or S(0) q R q .
  • Rn is H.
  • each of R 2 and R 4 is H or C -C alkyl optionally substituted with amino, mono-Q-Ce alkylamino, di-CrC 6 alkylamino, or C 6 -C 10 aryl.
  • each of R 2 and R 4 independently is C C ? alkyl optionally substituted withCi-C 6 alkoxyl.
  • each of R 2 and R 4 is methyl.
  • R is H.
  • R 12 is H, methyl, ethyl, ethenyl, or halo.
  • R 12 is methyl.
  • R 12 is ethyl.
  • R 12 is ethenyl
  • R 8 is H, methyl, ethyl, or ethenyl.
  • R 8 is methyl
  • Rg is ethyl
  • Rg is 4 to 7-membered heterocycloalkyl (e.g., azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, triazolidinyl, tetrahyrofuranyl, piperidinyl, 1,2,3,6-tetrahydropyridinyl, piperazinyl, tetrahydro-2H-pyranyl, 3,6-dihydro-2H-pyranyl, tetrahydro-2H-thiopyran, morpholinyl, 1,4-diazepanyl, 1,4-oxazepanyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl, 2,5-diazabicyclo[2.2.1]heptanyl, and the like).
  • heterocycloalkyl
  • Rg is tetrahydropyran.
  • Rg is tetrahydropyran and R 7 is -Q 4 -T 4 , in which Q 4 is a bond or C C 4 alkyl linker and T 4 is H, CrC 6 alkyl, C 3 -Cg cycloalkyl or 4 to 7-membered heterocycloalkyl.
  • ⁇ is NR 7 Rg or CR 7 RgR 14 wherein R 7 and Rg, together with the atom to which they are attached, form a 4 to 11-membered heterocycloalkyl ring having 1 to 3 heteroatoms (e.g., azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, triazolidinyl, tetrahyrofuranyl, piperidinyl, 1,2,3,6- tetrahydropyridinyl, piperazinyl, tetrahydro-2H-pyranyl, 3,6-dihydro-2H-pyranyl, tetrahydro-2H- thiopyran, and morpholinyl, and the like) or C 3 -Cg cycloalkyl, each optionally substituted
  • the ring formed by R 7 and Rg is selected from the group consisting of azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, and cyclohexenyl, each optionally substituted with one -Q6-T 6 .
  • -Q6-T 6 is oxo.
  • T 6 is H, halo, CrC 6 alkyl, CrC 6 alkoxyl, C 3 -Cg cycloalkyl, C6-C 10 aryl, or 4 to 7-membered heterocycloalkyl.
  • Q 6 is a bond and T 6 is Ci-C alkyl, C 3 -Cg cycloalkyl, or 4 to 7-membered heterocyclo alkyl .
  • Q 6 is CO, S(0) 2 , or NHC(O); and T 6 is Ci-Ce alkyl, Q-Ce alkoxyl, C 3 -C 8 cycloalkyl, or 4 to 7-membered heterocycloalkyl.
  • T 6 is CrC 6 alkyl or CrC 6 alkoxyl, each optionally substituted with halo, hydroxyl, cyano, CrC 6 alkoxyl, amino, mono-Ci-C 6 alkylamino, di-C C 6 alkylamino, or C 3 -C 8 cycloalkyl.
  • Q 6 is Ci-C 3 alkyl linker and T 6 is H or C 6 -Cio aryl.
  • Q 6 is CrC 3 alkyl linker and T 6 is C 3 -C 8 cycloalkyl, 4 to 7-membered heterocycloalkyl, or S(0) p R p .
  • each of R p and R q is C -C alkyl.
  • R 13 is H or methyl.
  • R 13 is H.
  • R3 is H.
  • A is Br ⁇ .
  • each of R5, R 9 , and R 10 is H.
  • each of R a and R independently is H or C -C alkyl optionally substituted
  • R a and R b are H.
  • R a and R b together with the N atom to which they are attached, form a 4 to 7-membered heterocycloalkyl ring having 0 or 1 additional heteroatoms to the N atom (e.g., azetidinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, triazolidinyl, piperidinyl, 1,2,3,6-tetrahydropyridinyl, piperazinyl, morpholinyl, 1,4-diazepanyl, 1,4- oxazepanyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl, 2,5-diazabicyclo[2.2.1]heptanyl, and the like) and the ring is optionally substituted with one or more -Q3-T 3.
  • R a and R together with the N atom to which they are attached, form azetidinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, triazolidinyl, tetrahyrofuranyl, piperidinyl, 1,2,3,6-tetrahydropyridinyl, piperazinyl, or morpholinyl, and the ring is optionally substituted with one or more -Q3-T 3 .
  • one or more -Q3-T 3 are oxo.
  • Q 3 is a bond or unsubstituted or substituted C C 3 alkyl linker.
  • T 3 is H, halo, 4 to 7-membered heterocycloalkyl, C C 3 alkyl, OR d , COOR d ,-S(0) 2 Rd, or -NR d Re.
  • one of Ra and R e is H.
  • R 7 is C 3 -C8 cycloalkyl or 4 to 7-membered heterocycloalkyl, each optionally substituted with one or more -Q5-T 5 .
  • R 7 is piperidinyl, tetrahydropyran, tetrahydro-2H-thiopyranyl, cyclopentyl, cyclohexyl, pyrrolidinyl, or cycloheptyl, each optionally substituted with one or more -Q5-T5.
  • R 7 is cyclopentyl cyclohexyl or tetrahydro-2H-thiopyranyl, each optionally substituted with one or more -Q5-T 5 .
  • Q5 is NHC(O) and T 5 is C C 6 alkyl or C C 6 alkoxy.
  • one or more -Q5-T5 are oxo.
  • R 7 is l-oxide-tetrahydro-2H-thiopyranyl or l,l-dioxide-tetrahydro-2H- thiopyranyl.
  • Q5 is a bond and T 5 is amino, mono-Ci-C 6 alkylamino, di-C C 6 alkylamino.
  • Q 5 is CO, S(0) 2 , or NHC(O); and T 5 is Ci-C 6 alkyl, Ci-C 6 alkoxyl, C 3 -C 8 cycloalkyl, or 4 to 7-membered heterocycloalkyl.
  • Rg is H, methyl, or ethyl.
  • the compounds suitable for use in the method of this invention also include compounds of Formula (III):
  • Xi' is N or CR n ';
  • X 2 ' is N or CR 13 ';
  • X is N or C, and when X is N, R 6 ' is absent;
  • Z 2 is NR 7 'R 8 ⁇ OR 7 ', S(0)a ⁇ R 7 ', or CR 7 'R 8 'R 14 ', in which a' is 0, 1, or 2;
  • each of R , R 5 ', Rg', and Rio' is H or C C 6 alkyl optionally substituted with one or more substituents selected from the group consisting of halo, hydroxyl, COOH, C(0)0-C 1 -C 6 alkyl, cyano, Ci-C 6 alkoxyl, amino, mono-C Ce alkylamino, di-C ⁇ Ce alkylamino, C 3 -C8 cycloalkyl, C 6 -C 10 aryl, 4 to 12-membered heterocycloalkyl, and 5- or 6-membered heteroaryl;
  • each of R 2 ', R ', and R 4 ' is -Q -TY, in which is a bond or C C 3 alkyl linker optionally substituted with halo, cyano, hydroxyl or Ci-C 6 alkoxy, and TY is H, halo, hydroxyl, COOH, cyano, azido, or Rsi', in which Rsi' is CrC 3 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C C 6 alkoxyl, C(0)0-CrC 6 alkyl, C 3 -C8 cycloalkyl, C 6 -C 10 aryl, amino, mono-Q-Ce alkylamino, di-Q-Ce alkylamino, 4 to 12-membered heterocycloalkyl, or 5- or 6-membered heteroaryl, and R sl ' is optionally substituted with one or more substituents selected from the group consisting of halo,
  • R 6 ' is H, halo, cyano, azido, OR a ', -NR a 'R b ', -C(0)R a ', -C(0)OR a ', -C(0)NR a 'R b ', -NR b 'C(0)R a ', -S(0)b ⁇ R a ', -S(0)b'NR a 'R b ', or R S2 ', in which R S2 ' is Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C3-C 8 cycloalkyl, or 4 to 12-membered heterocycloalkyl, b' is 0, 1, or 2, each of R a ' and R b ', independently is H or Rs 3 ', and Rs 3 ' is CrC 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkyny
  • R 7 ' is -Q 4 '-T 4 ', in which Q 4 ' is a bond, CrC 4 alkyl linker, or C 2 -C 4 alkenyl linker, each linker optionally substituted with halo, cyano, hydroxyl or CrC 6 alkoxy, and T 4 ' is H, halo, cyano, NR g 'R h ', -OR g ' , -C(0)R g ' , -C(0)OR g ' , -C(0)NR g 'R h ', -C(0)NR g 'OR h ' , -NR g 'C(0)R h ', - S(0) 2 R g ', or Rs 6 in which each of R g ' and R h ' , independently is H or Rs 7 ', each of R s6 ' and Rs 7 ', independently is CrC 6 alkyl, C 2 -C 6 alken
  • R 7 ' is not H
  • each of R 8 ', Rn ⁇ R12' , and R 13 ' is H, halo, hydroxyl, COOH, cyano, R S8 ⁇ OR S8 ⁇ or COORss', in which R S8 ' is Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, 4 to 12-membered heterocycloalkyl, amino, mono-Ci-C 6 alkylamino, or di-C C 6 alkylamino, and Rsg' is optionally substituted with one or more substituents selected from the group consisting of halo, hydroxyl, COOH, C(0)0-C 1 -C 6 alkyl, cyano, C -C alkoxyl, amino, mono-Ci-Ce alkylamino, and di-C ⁇ Ce alkylamino; or R 7 ' and R 8 ', together with the N atom
  • R 14 ' is absent, H, or Ci-C 6 alkyl optionally substituted with one or more substituents selected from the group consisting of halo, hydroxyl, COOH, C(0)0-C 1 -C 6 alkyl, cyano, Ci-C 6 alkoxyl, amino, mono-Q-Ce alkylamino, di-C C 6 alkylamino, C 3 -Cg cycloalkyl, C 6 -C 10 aryl, 4 to 12-membered heterocycloalkyl, and 5- or 6-membered heteroaryl.
  • substituents selected from the group consisting of halo, hydroxyl, COOH, C(0)0-C 1 -C 6 alkyl, cyano, Ci-C 6 alkoxyl, amino, mono-Q-Ce alkylamino, di-C C 6 alkylamino, C 3 -Cg cycloalkyl, C 6 -C 10 aryl, 4 to 12-membered heterocycloalkyl,
  • One subset of the compounds of Formula (III) includes those of Formula (Ilia):
  • Another subset of the compounds of Formula (III) includes those of Formula (Illb), (II
  • the compounds of Formulae (III), (Ilia), (Illb), (IIIc), and (Hid) can include one or more of the following features:
  • X 2 ' is CR 13 ' .
  • X is CRn' and X 2 ' is N.
  • X is N and X 2 ' is CR 13 ' .
  • X is N and X 2 ' is N.
  • X 3 is C.
  • X 3 is N and R 6 ' is absent.
  • Z 2 is NRv'Rg' .
  • Z 2 is CRv'Rg'Rn' .
  • Z 2 is OR 7 ' .
  • Z 2 is S(0) a 'R7' , in which a' is 0, 1, or 2 .
  • R 6 ' is H.
  • R 6 ' is halo (e.g. , fluorine, chlorine, bromine, and iodine).
  • R 6 ' is CrC 3 alkyl optionally substituted with one or more -Q 2 '-T 2 ' .
  • R 6 ' is CF 3 .
  • R 6 ' is C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, or C 3 -C 6 cycloalkyl each optionally substituted with one or more -Q 2 '-T 2 ' .
  • R 6 ' is ethenyl
  • R 6 ' is ethynyl.
  • R 6 ' is ethynyl substituted with one or more -Q 2 '-T 2 ', in which Q 2 ' is a bond or Ci-C 3 alkyl linker and T 2 ' is C -C alkyl, C 3 -C 6 cycloalkyl, or 4 to 7-membered
  • heterocycloalkyl e.g., azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, triazolidinyl, tetrahyrofuranyl, piperidinyl, 1,2,3,6- tetrahydropyridinyl, piperazinyl, tetrahydro-2H-pyranyl, 3,6-dihydro-2H-pyranyl, tetrahydro-2H- thiopyranyl, 1,4-diazepanyl, 1,4-oxazepanyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl, 2,5- diazabicyclo[2.2.1]heptanyl, and morpholinyl, and the like) optionally substituted with one or
  • R 6 ' is cyano
  • R 6 ' is azido
  • R 6 ' is C(0)H.
  • R 6 ' is OR a ' or -C(0)R a ' .
  • R a ' is C -C alkyl or 4 to 7-membered heterocycloalkyl (e.g., azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, triazolidinyl, tetrahyrofuranyl, piperidinyl, 1,2,3,6-tetrahydropyridinyl, piperazinyl, tetrahydro- 2H-pyranyl, 3,6-dihydro-2H-pyranyl, tetrahydro-2H-thiopyranyl, 1,4-diazepanyl, 1,4- oxazepanyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl, 2,5-diazabicyclo[2.2.1]heptanyl, and morph
  • R 6 ' is 4 to 7-membered heterocycloalkyl (e.g., azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, triazolidinyl, tetrahyrofuranyl, piperidinyl, 1,2,3,6-tetrahydropyridinyl, piperazinyl, tetrahydro-2H-pyranyl, 3,6-dihydro-2H-pyranyl, tetrahydro-2H-thiopyranyl, 1,4-diazepanyl, 1,4-oxazepanyl, 2-oxa-5- azabicyclo[2.2.1]heptanyl, 2,5-diazabicyclo[2.2.1]heptanyl, and morpholinyl, and the like) optionally
  • R 6 ' is piperidinyl, 2,2,6,6-tetramethyl-piperidinyl, 1,2,3,6- tetrahydropyridinyl, 2,2,6,6-tetramethyl- 1,2,3,6-tetrahydropyridinyl, piperazinyl, morpholinyl, tetrahydro-2H-pyranyl, 3,6-dihydro-2H-pyranyl, or pyrrolidinyl, each of which is optionally substituted with one or more -Q 2 '-T 2 ' .
  • R 6 ' is 4 to 7-membered heterocycloalkyl optionally substituted with one or more -Q 2 '-T 2 ', and -Q 2 '-T 2 ' is oxo or Q 2 ' is a bond and T 2 ' is -OR c ', -NR c 'R d ', -C(0)R c ', -C(0)OR c ', -S(0) 2 R c ', CrC 6 alkyl, or 4 to 7-membered heterocycloalkyl, each of which is optionally substituted with one or more -Q 3 '-T ' when R c ' or Ra' is not H.
  • R 6 ' is -NR a 'R b ', -C(0)R a ', -C(0)OR a ', -C(0)NR a 'R b ', -NR b 'C(0)R a ', -SR a ', -S(0) 2 R a ', or -S(0) 2 NR a 'R b ' .
  • each of R a ' and R b ' independently is H, C C 6 alkyl, or C 3 -C8 cycloalkyl optionally substituted with one or more -Q 2 '-T 2 ⁇
  • one of R a ' and R b ' is H.
  • R a ' and R b ' together with the N atom to which they are attached, form a 4 to 7-membered heterocycloalkyl ring having 0 or 1 additional heteroatoms to the N atom (e.g., azetidinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, triazolidinyl, piperidinyl, 1,2,3,6-tetrahydropyridinyl, piperazinyl, 1,4-diazepanyl, 1,4-oxazepanyl, 2-oxa-5- azabicyclo[2.2.1]heptanyl, 2,5-diazabicyclo[2.2.1]heptanyl, and morpholinyl, and the like) and the ring is optionally substituted with one or more -Q 2 '-T 2 '
  • -Q 2 '-T 2 ' is oxo.
  • Q 2 ' is a bond
  • Q 2 ' is an unsubstituted CrC 3 alkyl linker.
  • T 2 ' is C -C alkyl or C6-Cio aryl, each optionally substituted with one or more -Q 3 '-T 3 ' .
  • T 2 ' is an unsubstituted substituted straight chain CrC 6 or branched C 3 -C 6 alkyl, including but not limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, t-butyl, n-pentyl, s-pentyl and n-hexyl.
  • T 2 ' is phenyl
  • T 2 ' is halo (e.g. , fluorine, chlorine, bromine, and iodine).
  • T 2 ' is 4 to 7-membered heterocycloalkyl (e.g., azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, triazolidinyl, tetrahyrofuranyl, piperidinyl, 1,2,3,6-tetrahydropyridinyl, piperazinyl, tetrahydro-2H-pyranyl, 3,6-dihydro-2H-pyranyl, tetrahydro-2H-thiopyranyl, 1,4-diazepanyl, 1,4-oxazepanyl, 2-oxa-5- azabicyclo[2.2.1]heptanyl, 2,5-diazabicyclo[2.2.1]heptanyl, and morpholinyl, and the like) optionally
  • T 2 ' is -OR c ', -NR c 'R d ', -C(0)R c ', -C(0)OR c ', or -S(0) 2 R c ' .
  • R c ' is CrC 6 alkyl or 4 to 7-membered heterocycloalkyl (e.g., azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, triazolidinyl, tetrahyrofuranyl, piperidinyl, 1,2,3,6-tetrahydropyridinyl, piperazinyl, tetrahydro- 2H-pyranyl, 3,6-dihydro-2H-pyranyl, tetrahydro-2H-thiopyranyl, 1,4-diazepanyl, 1,4- oxazepanyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl, 2,5-diazabicyclo[2.2.1]heptanyl, and
  • each of R c ' and R d ' independently is H or CrC 6 alkyl optionally substituted with one or more
  • R c ' is H.
  • R d ' is H.
  • R c ' and R d ' together with the N atom to which they are attached, form a 4 to 7-membered heterocycloalkyl ring having 0 or 1 additional heteroatoms to the N atom (e.g., azetidinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, triazolidinyl, piperidinyl, 1,2,3,6-tetrahydropyridinyl, piperazinyl, 1,4-diazepanyl, 1,4-oxazepanyl, 2-oxa-5- azabicyclo[2.2.1]heptanyl, 2,5-diazabicyclo[2.2.1]heptanyl, and morpholinyl, and the like) and the ring is optionally substituted with one or more -Q 3 '-T 3 ' .
  • the ring is optionally substituted
  • Q 2 ' is a bond and T 2 ' is -OR c ', -NR c 'R d ', -C(0)R c ', -C(0)OR c ', -S(0) 2 R c ', C -C alkyl, or 4 to 7-membered heterocycloalkyl, each of which is optionally substituted with one or more -Q 3 '-T 3 ' when R c ' or R d ' is not H.
  • T 2 ' is 4 to 7-membered heterocycloalkyl or C 3 -Cg cycloalkyl and one or more -Q 3 '-T 3 ' are oxo.
  • Q 3 ' is a bond or unsubstituted or substituted CrC 3 alkyl linker.
  • T 3 ' is H, halo, 4 to 7-membered heterocycloalkyl, CrC 3 alkyl, OR e ', COORe',-S(0) 2 R e ',-NR e 'Rf', or -C(0)NR e 'R f ' .
  • R d ' and R e ' is H.
  • Q 3 ' is a bond or CrC 3 alkyl linker and T 3 ' is selected from the group consisting of C C 3 alkyl, halo, OR e ', -S(0) 2 R e ', -NR e 'R f ', and-C(0)NR e 'R f ' .
  • Q 3 ' is a bond or C C 3 alkyl linker and T 3 ' is selected from the group consisting of C C 3 alkyl, OR e ', -S(0) 2 R e ', or -NR e 'R f ' .
  • R e ' is H.
  • R f ' is H.
  • R 7 ' is -C(0)R g ' .
  • R 7 ' is -C(0)R g ', in which R g ' is C 3 -Cg cycloalkyl, 4 to 7-membered heterocycloalkyl, C 3 -C8 cycloalkyl.
  • R 7 ' is C6-C 10 aryl substituted with one or more -Qs'-Ts' .
  • R 7 ' is phenyl optionally substituted with one or more -Qs'-Ts' .
  • R 7 ' is CrC 6 alkyl optionally substituted with one or more -Qs'-Ts' .
  • R 7 ' is C 3 -C 8 cycloalkyl optionally substituted with one or more
  • R 7 ' is 4 to 7-membered heterocyclo alkyl (e.g., azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, triazolidinyl, tetrahyrofuranyl, piperidinyl, 1,2,3,6-tetrahydropyridinyl, piperazinyl, tetrahydro-2H-pyranyl, 3,6-dihydro-2H-pyranyl, tetrahydro-2H-thiopyranyl, 1,4-diazepanyl, 1,4-oxazepanyl, 2-oxa-5- azabicyclo[2.2.1]heptanyl, 2,5-diazabicyclo[2.2.1]heptanyl, and morpholinyl, and the like) optionally
  • R 7 ' is 5 to 6-membered heterocyclo alkyl optionally substituted with one or more -Q 5 '-T 5 ' .
  • R 7 ' is isopropyl
  • R 7 ' is pyrrolidinyl, piperidinyl, tetrahydropyran, cyclopentyl, or cyclohexyl, cycloheptyl, each optionally substituted with one -Qs'-Ts' .
  • R 7 ' is cyclopentyl or cyclohexyl, each optionally substituted with one -Qs'- Ts' .
  • Q 5 ' is NHC(O) and T 5 ' is CrC 6 alkyl or CrC 6 alkoxy.
  • -Qs'-Ts' is oxo
  • T 4 ' is 4 to 7-membered heterocycloalkyl, C 3 -C 8 cycloalkyl, or C 6 -Cio aryl, and one or more -Qs'-Ts' are oxo.
  • R 7 ' is l-oxide-tetrahydro-2H-thiopyranyl or l, l-dioxide-tetrahydro-2H- thiopyranyl.
  • R 7 ' is cyclohexanonyl, e.g., cyclohexanon-4-yl.
  • T 5 ' is H, halo, C -C alkyl, C -C alkoxyl, C 3 -C 8 cycloalkyl, C 6 -Cio aryl, or 4 to 7-membered heterocycloalkyl.
  • Q 5 ' is a bond and T 5 ' is CrC 6 alkyl, C 3 -C 8 cycloalkyl, or 4 to 7-membered heterocyclo alkyl .
  • Q5' is a bond and T 5 ' is 5- or 6-membered heteroaryl, amino, mono-Q-Ce alkylamino, di-C C 6 alkylamino, T 5 ' being optionally substituted with one or more substituents selected from the group consisting of halo, hydroxyl, CrC 6 alkoxyl, or C 3 -C 8 cycloalkyl.
  • Q 5 ' is CO, S(0) 2 , or NHC(O); and T 5 ' is Ci-C 6 alkyl, Ci-C 6 alkoxyl, C 3 -C 8 cycloalkyl, or 4 to 7-membered heterocycloalkyl.
  • T 5 ' is C -C alkyl or C -C alkoxyl, each optionally substituted with halo, hydroxyl, cyano, C -C alkoxyl, amino, mono-C Ce alkylamino, di-C ⁇ Ce alkylamino, or C 3 -Cg cycloalkyl.
  • (3 ⁇ 4' is CrC 3 alkyl linker and T 5 ' is H or C6-C 10 aryl.
  • (3 ⁇ 4' is Q-C3 alkyl linker and T 5 ' is C 3 -Cg cycloalkyl, 4 to 7-membered heterocycloalkyl, or S(0) q 'R q ' .
  • R 6 ' is halo (e.g. , fluorine, chlorine, bromine, and iodine) and Z 2 is S(0) a R 7 ', in which a' is 0, 1, or 2 and R 7 ' is CrC 6 alkyl (e.g., methyl, ethyl, n-propyl, i-propyl, butyl, or t- butyl), C 3 -Cg cycloalkyl (e.g., cyclopentyl, cyclohexyl, or cycloheptyl) or 4 to 7-membered heterocycloalkyl (e.g., azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, triazolidinyl, tetrahyrofurany
  • R 6 ' is halo (e.g. , fluorine, chlorine, bromine, and iodine) and Z 2 is OR 7 ' .
  • R 7 ' is 4 to 7-membered heterocycloalkyl (e.g., azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, triazolidinyl, tetrahyrofuranyl, piperidinyl, 1,2,3,6-tetrahydropyridinyl, piperazinyl, tetrahydro-2H-pyranyl, 3,6-dihydro-2H- pyranyl, tetrahydro-2H-thiopyranyl, 1,4-diazepanyl, 1,4-oxazepanyl, 2-oxa-5-
  • Rn ' is H.
  • each of R 2 ' and R 4 ' is H or CrC 6 alkyl optionally substituted with azido, halo, amino, mono-C Ce alkylamino, di-C ⁇ Ce alkylamino, or C6-Q0 aryl.
  • each of R 2 ' and R 4 ' independently is CrC 3 alkyl optionally substituted with C C 6 alkoxyl.
  • each of R 2 ' and R 4 ' is methyl.
  • R 2 ' and R 4 ' is methyl.
  • R 4 ' is H.
  • C C 6 alkyl optionally substituted with azido, halo, amino, mono-Cr C alkylamino, di-C ⁇ Ce alkylamino, or C 6 -Cio aryl.
  • R 12 ' is H, methyl, ethyl, ethenyl, or halo.
  • R 12 ' is methyl
  • R 12 ' is ethyl
  • R 12 ' is ethenyl or propenyl.
  • R 12 ' is methoxyl
  • Rg' is H, methyl, ethyl, or ethenyl.
  • Rg' is methyl
  • Rg' is ethyl
  • Rg' is propyl
  • Rg' is ethenyl or propenyl.
  • Rg' is C C 6 alkyl substituted with one or more substituents selected from the group consisting of halo (e.g., F, CI, or Br), hydroxyl, or Ci-C 6 alkoxyl.
  • halo e.g., F, CI, or Br
  • Rg' is 4 to 7-membered optionally substituted heterocycloalkyl (e.g., azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, triazolidinyl, tetrahyrofuranyl, piperidinyl, 1,2,3,6-tetrahydropyridinyl, piperazinyl, tetrahydro-2H-pyranyl, 3,6-dihydro-2H-pyranyl, tetrahydro-2H-thiopyranyl, 1,4- diazepanyl, 1,4-oxazepanyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl, 2,5-diazabicyclo[2.2.1]heptanyl, and morpholinyl, and the like).
  • Rg' is piperidinyl
  • Rg' is 4 to 7-membered optionally substituted heterocycloalkyl and R 7 ' is -Q 4 '-T 4 ', in which Q 4 ' is a bond or C C 4 alkyl linker and T 4 ' is H, Ci-C 6 alkyl, C 3 -Cg cycloalkyl or 4 to 7-membered heterocycloalkyl.
  • Z 2 is NR 7 'Rg' or CR 7 'Rg'R 14 ' wherein R 7 ' and Rg', together with the atom to which they are attached, form a 4 to 11-membered heterocycloalkyl ring having 1 to 3 heteroatoms (e.g., azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, triazolidinyl, tetrahyrofuranyl, piperidinyl, 1,2,3,6- tetrahydropyridinyl, piperazinyl, tetrahydro-2H-pyranyl, 3,6-dihydro-2H-pyranyl, tetrahydro-2H- thiopyranyl, 1,4-diazepanyl, 1,4-oxaze
  • the ring formed by R 7 ' and R 8 ' is selected from the group consisting of azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, and cyclohexenyl, each optionally substituted with one -Q 6 '-T 6 ' .
  • -Q 6 '-T 6 ' is oxo.
  • T 6 ' is H, halo, C -C alkyl, C -C alkoxyl, C3-C 8 cycloalkyl, C 6 -Cio aryl, or 4 to 7-membered heterocycloalkyl.
  • (3 ⁇ 4' is a bond and T 6 is CrC 6 alkyl, C3-C 8 cycloalkyl, or 4 to 7-membered heterocyclo alkyl .
  • Q 6 ' is CO, S(0) 2 , or NHC(O); and T 6 ' is Ci-C 6 alkyl, Ci-C 6 alkoxyl, C 3 -C 8 cycloalkyl, or 4 to 7-membered heterocycloalkyl.
  • T 6 ' is CrC 6 alkyl or CrC 6 alkoxyl, each optionally substituted with halo, hydroxyl, cyano, CrC 6 alkoxyl, amino, mono-Ci-C 6 alkylamino, di-CrC 6 alkylamino, or C 3 -C 8 cycloalkyl.
  • Q 6 ' is Q-C3 alkyl linker and T 6 ' is H or C 6 -C 10 aryl.
  • Q 6 ' is CrC 3 alkyl linker and T 6 ' is C 3 -C 8 cycloalkyl, 4 to 7-membered heterocycloalkyl, or S(0) p 'R p ' .
  • each of R p ' and R q ' is C -C alkyl.
  • R 6 ' is -S(0) b 'R a ' or azido, in which b' is 0, 1, or 2 and R a ' is C -C alkyl or C 3 -C 8 cycloalkyl; and Z 2 is NR 7 'Rs' , in which R 7 ' is C 3 -C 8 cycloalkyl (e.g., cyclopentyl, cyclohexyl, or cycloheptyl) or 4 to 7-membered heterocycloalkyl (e.g., azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, triazolidinyl, tetrahyrofuranyl, piperidinyl, 1,2,3,6-tetrahydropyridinyl, pipe
  • R 6 ' is halo (e.g. , fluorine, chlorine, bromine, and iodine) and Z 2 is NR 7 'Rs' or CR 7 'R8'Ri 4 ' wherein R 7 ' and Rs' , together with the atom to which they are attached, form a 4 to 11-membered heterocycloalkyl ring having 1 to 3 heteroatoms (e.g., azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, triazolidinyl, tetrahyrofuranyl, piperidinyl, 1,2,3,6-tetrahydropyridinyl, piperazinyl, tetrahydro-2H-pyranyl, 3,6-dihydro-2H-pyranyl, t
  • R 13 ' is H or methyl.
  • R 13 ' is H.
  • R ' is H.
  • each of R5' , R9' , and Rio' is H.
  • Exemplary EZH2 inhibitor compounds of the present invention are shown in Table 1.
  • substituted means substituted by one or more defined groups.
  • groups may be selected from a number of alternative groups the selected groups may be the same or different.
  • an "effective amount” means that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal or human that is being sought, for instance, by a researcher or clinician.
  • therapeutically effective amount means any amount which, as compared to a corresponding subject who has not received such amount, results in improved treatment, healing, prevention, or amelioration of a disease, disorder, or side effect, or a decrease in the rate of advancement of a disease or disorder.
  • the term also includes within its scope amounts effective to enhance normal physiological function.
  • alkyl As used herein, "alkyl”, “C C 2 , C 3 , C 4 , C 5 or C 6 alkyl” or “C C 6 alkyl” is intended to include C 1 ; C 2 , C 3 , C 4 , C 5 or C 6 straight chain (linear) saturated aliphatic hydrocarbon groups and C 3 , C 4 , C 5 or C branched saturated aliphatic hydrocarbon groups.
  • C1-C6 alkyl is intended to include Ci, C2, C3, C4, C5 and Ce alkyl groups.
  • alkyl examples include, moieties having from one to six carbon atoms, such as, but not limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, t-butyl, n-pentyl, s-pentyl or n-hexyl.
  • a straight chain or branched alkyl has six or fewer carbon atoms (e.g. , Ci-C6 for straight chain, C 3 -C 6 for branched chain), and in another embodiment, a straight chain or branched alkyl has four or fewer carbon atoms.
  • cycloalkyl refers to a saturated or unsaturated nonaromatic hydrocarbon mono-or multi-ring (e.g., fused, bridged, or spiro rings) system having 3 to 30 carbon atoms (e.g., C 3 -Cio).
  • cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, and adamantyl.
  • heterocycloalkyl refers to a saturated or unsaturated nonaromatic 3-8 membered monocyclic, 7-12 membered bicyclic (fused, bridged, or spiro rings), or 11-14 membered tricyclic ring system (fused, bridged, or spiro rings) having one or more heteroatoms (such as O, N, S, or Se), unless specified otherwise.
  • heterocycloalkyl groups include, but are not limited to, piperidinyl, piperazinyl, pyrrolidinyl, dioxanyl, tetrahydrofuranyl, isoindolinyl, indolinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, triazolidinyl, tetrahyrofuranyl, oxiranyl, azetidinyl, oxetanyl, thietanyl, 1,2,3,6- tetrahydropyridinyl, tetrahydropyranyl, dihydropyranyl, pyranyl, morpholinyl, 1,4-diazepanyl, 1,4-oxazepanyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl, 2,5-diazabicyclo[2.2.1]heptanyl, and
  • substituents can include, for example, alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, amino (including alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino), acylamino (including alkylcarbonylamino, ary
  • arylalkyl or an “aralkyl” moiety is an alkyl substituted with an aryl (e.g. , phenylmethyl (benzyl)).
  • alkylaryl moiety is an aryl substituted with an alkyl (e.g. , methylphenyl).
  • alkyl linker is intended to include C 1 ; C 2 , C 3 , C 4 , C 5 or C 6 straight chain (linear) saturated divalent aliphatic hydrocarbon groups and C 3 , C 4 , C 5 or C 6 branched saturated aliphatic hydrocarbon groups.
  • C1-C6 alkyl linker is intended to include Ci, C2, C3, C4, C5 and ⁇ alkyl linker groups.
  • alkyl linker examples include, moieties having from one to six carbon atoms, such as, but not limited to, methyl (-CH 2 -), ethyl (-CH 2 CH 2 -), n-propyl (- CH 2 CH 2 CH 2 -), i-propyl (-CHCH 3 CH 2 -), n-butyl (-CH 2 CH 2 CH 2 CH 2 -), s-butyl (-CHCH 3 CH 2 CH 2 - ), i-butyl (-C(CH 3 ) 2 CH 2 -), n-pentyl (-CH 2 CH 2 CH 2 CH 2 CH 2 -), s-pentyl (-CHCH 3 CH 2 CH 2 CH 2 -) or n-hexyl (-CH 2 CH 2 CH 2 CH 2 CH 2 -).
  • alkenyl includes unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that contain at least one double bond.
  • alkenyl includes straight chain alkenyl groups (e.g. , ethenyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, nonenyl, decenyl), and branched alkenyl groups.
  • a straight chain or branched alkenyl group has six or fewer carbon atoms in its backbone (e.g. , C 2 -C 6 for straight chain, C 3 -C 6 for branched chain).
  • C 2 - C 6 includes alkenyl groups containing two to six carbon atoms.
  • C 3 -C6 includes alkenyl groups containing three to six carbon atoms.
  • optionally substituted alkenyl refers to unsubstituted alkenyl or alkenyl having designated substituents replacing one or more hydrogen atoms on one or more hydrocarbon backbone carbon atoms. Such substituents can include, for example, alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy,
  • aryloxycarbonyloxy carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, amino (including alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, heterocyclyl,
  • Alkynyl includes unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but which contain at least one triple bond.
  • alkynyl includes straight chain alkynyl groups (e.g. , ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl, decynyl), and branched alkynyl groups.
  • a straight chain or branched alkynyl group has six or fewer carbon atoms in its backbone (e.g.
  • C 2 -C 6 for straight chain, C 3 -C 6 for branched chain).
  • C 2 -C 6 includes alkynyl groups containing two to six carbon atoms.
  • C 3 -C 6 includes alkynyl groups containing three to six carbon atoms.
  • alkynyl refers to unsubstituted alkynyl or alkynyl having designated substituents replacing one or more hydrogen atoms on one or more hydrocarbon backbone carbon atoms.
  • substituents can include, for example, alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy,
  • aryloxycarbonyloxy carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, amino (including alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, hetero
  • optionally substituted moieties include both the unsubstituted moieties and the moieties having one or more of the designated substituents.
  • substituted heterocycloalkyl includes those substituted with one or more alkyl groups, such as 2,2,6, 6-tetramethyl-piperidinyl and 2,2,6, 6-tetramethyl- 1 ,2,3,6-tetrahydropyridinyl.
  • Aryl includes groups with aromaticity, including “conjugated,” or multicyclic systems with at least one aromatic ring and do not contain any heteroatom in the ring structure.
  • Examples include phenyl, benzyl, 1,2,3,4-tetrahydronaphthalenyl, etc.
  • Heteroaryl groups are aryl groups, as defined above, except having from one to four heteroatoms in the ring structure, and may also be referred to as “aryl heterocycles" or
  • heteroaryl is intended to include a stable 5-, 6-, or 7-membered monocyclic or 7-, 8-, 9-, 10-, 11- or 12-membered bicyclic aromatic heterocyclic ring which consists of carbon atoms and one or more heteroatoms, e.g. , 1 or 1-2 or 1-3 or 1-4 or 1-5 or 1-6 heteroatoms, or e.g. ⁇ l, 2, 3, 4, 5, or 6 heteroatoms, independently selected from the group consisting of nitrogen, oxygen and sulfur.
  • the nitrogen atom may be substituted or unsubstituted (i.e. , N or NR wherein R is H or other substituents, as defined).
  • heteroaryl groups include pyrrole, furan, thiophene, thiazole, isothiazole, imidazole, triazole, tetrazole, pyrazole, oxazole, isoxazole, pyridine, pyrazine, pyridazine, pyrimidine, and the like.
  • aryl and heteroaryl include multicyclic aryl and heteroaryl groups, e.g. , tricyclic, bicyclic, e.g. , naphthalene, benzoxazole, benzodioxazole, benzothiazole, benzoimidazole, benzothiophene, methylenedioxyphenyl, quinoline, isoquinoline, naphthrydine, indole, benzofuran, purine, benzofuran, deazapurine, indolizine.
  • the rings In the case of multicyclic aromatic rings, only one of the rings needs to be aromatic (e.g. , 2,3-dihydroindole), although all of the rings may be aromatic (e.g. , quinoline).
  • the second ring can also be fused or bridged.
  • the cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring can be substituted at one or more ring positions (e.g., the ring-forming carbon or heteroatom such as N) with such substituents as described above, for example, alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkoxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkylaminocarbonyl, aralkylaminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, aralkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, aminocarbonyl,
  • alkylthiocarbonyl phosphate, phosphonato, phosphinato, amino (including alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino), acylamino (including
  • Aryl and heteroaryl groups can also be fused or bridged with alicyclic or heterocyclic rings, which are not aromatic so as to form a multicyclic system (e.g. , tetralin,
  • Carbocycle or “carbocyclic ring” is intended to include any stable monocyclic, bicyclic or tricyclic ring having the specified number of carbons, any of which may be saturated, unsaturated, or aromatic.
  • Carbocycle includes cycloalkyl and aryl.
  • a C3-Q4 carbocycle is intended to include a monocyclic, bicyclic or tricyclic ring having 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 carbon atoms.
  • carbocycles include, but are not limited to, cyclopropyl, cyclobutyl, cyclobutenyl, cyclopentyl, cyclopentenyl, cyclohexyl, cycloheptenyl, cycloheptyl, cycloheptenyl, adamantyl, cyclooctyl, cyclooctenyl, cyclooctadienyl, fluorenyl, phenyl, naphthyl, indanyl, adamantyl and tetrahydronaphthyl.
  • Bridged rings are also included in the definition of carbocycle, including, for example, [3.3.0]bicyclooctane, [4.3.0]bicyclononane, [4.4.0]bicyclodecane and [2.2.2]bicyclooctane.
  • a bridged ring occurs when one or more carbon atoms link two non-adjacent carbon atoms.
  • bridge rings are one or two carbon atoms. It is noted that a bridge always converts a monocyclic ring into a tricyclic ring. When a ring is bridged, the substituents recited for the ring may also be present on the bridge. Fused (e.g. , naphthyl, tetrahydronaphthyl) and spiro rings are also included.
  • heterocycle or “heterocyclic group” includes any ring structure
  • Heterocycle includes heterocycloalkyl and heteroaryl.
  • heterocycles include, but are not limited to, morpholine, pyrrolidine, tetrahydrothiophene, piperidine, piperazine, oxetane, pyran, tetrahydropyran, azetidine, and tetrahydrofuran.
  • heterocyclic groups include, but are not limited to, acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl,
  • substituted means that any one or more hydrogen atoms on the designated atom is replaced with a selection from the indicated groups, provided that the designated atom's normal valency is not exceeded, and that the substitution results in a stable compound.
  • 2 hydrogen atoms on the atom are replaced.
  • Keto substituents are not present on aromatic moieties.
  • “Stable compound” and “stable structure” are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.
  • any variable e.g. , R
  • its definition at each occurrence is independent of its definition at every other occurrence.
  • the group may optionally be substituted with up to two Ri moieties and Ri at each occurrence is selected independently from the definition of Ri.
  • substituents and/or variables are permissible, but only if such combinations result in stable compounds.
  • hydroxy or "hydroxyl” includes groups with an -OH or -O " .
  • halo or halogen refers to fluoro, chloro, bromo and iodo.
  • perhalogenated generally refers to a moiety wherein all hydrogen atoms are replaced by halogen atoms.
  • haloalkyl or “haloalkoxyl” refers to an alkyl or alkoxyl substituted with one or more halogen atoms.
  • carbonyl includes compounds and moieties which contain a carbon connected with a double bond to an oxygen atom.
  • moieties containing a carbonyl include, but are not limited to, aldehydes, ketones, carboxylic acids, amides, esters, anhydrides, etc.
  • carboxyl refers to -COOH or its C 1 -C6 alkyl ester.
  • Acyl includes moieties that contain the acyl radical (R-C(O)-) or a carbonyl group.
  • substituted acyl includes acyl groups where one or more of the hydrogen atoms are replaced by, for example, alkyl groups, alkynyl groups, halogen, hydroxyl, alkylcarbonyloxy,
  • arylcarbonyloxy alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, amino (including alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino), acylamino (including
  • Aroyl includes moieties with an aryl or heteroaromatic moiety bound to a carbonyl group. Examples of aroyl groups include phenylcarboxy, naphthyl carboxy, etc. "Alkoxyalkyl,” “alkylaminoalkyl,” and “thioalkoxyalkyl” include alkyl groups, as described above, wherein oxygen, nitrogen, or sulfur atoms replace one or more hydrocarbon backbone carbon atoms.
  • alkoxy or "alkoxyl” includes substituted and unsubstituted alkyl, alkenyl and alkynyl groups covalently linked to an oxygen atom.
  • alkoxy groups or alkoxyl radicals include, but are not limited to, methoxy, ethoxy, isopropyloxy, propoxy, butoxy and pentoxy groups.
  • substituted alkoxy groups include halogenated alkoxy groups.
  • the alkoxy groups can be substituted with groups such as alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl,
  • halogen substituted alkoxy groups include, but are not limited to, fluoromethoxy, di
  • ether or "alkoxy” includes compounds or moieties which contain an oxygen bonded to two carbon atoms or heteroatoms.
  • alkoxyalkyl refers to an alkyl, alkenyl, or alkynyl group covalently bonded to an oxygen atom which is covalently bonded to an alkyl group.
  • esters includes compounds or moieties which contain a carbon or a heteroatom bound to an oxygen atom which is bonded to the carbon of a carbonyl group.
  • ester includes alkoxycarboxy groups such as methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, pentoxycarbonyl, etc.
  • thioalkyl includes compounds or moieties which contain an alkyl group connected with a sulfur atom.
  • the thioalkyl groups can be substituted with groups such as alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, carboxyacid, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, amino (including alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl
  • thiocarbonyl or "thiocarboxy” includes compounds and moieties which contain a carbon connected with a double bond to a sulfur atom.
  • thioether includes moieties which contain a sulfur atom bonded to two carbon atoms or heteroatoms.
  • examples of thioethers include, but are not limited to alkthioalkyls, alkthioalkenyls, and alkthioalkynyls.
  • alkthioalkyls include moieties with an alkyl, alkenyl, or alkynyl group bonded to a sulfur atom which is bonded to an alkyl group.
  • alkthioalkenyls refers to moieties wherein an alkyl, alkenyl or alkynyl group is bonded to a sulfur atom which is covalently bonded to an alkenyl group
  • alkthioalkynyls refers to moieties wherein an alkyl, alkenyl or alkynyl group is bonded to a sulfur atom which is covalently bonded to an alkynyl group.
  • amine or “amino” refers to unsubstituted or substituted -NH 2 .
  • Alkylamino includes groups of compounds wherein nitrogen of -NH 2 is bound to at least one alkyl group. Examples of alkylamino groups include benzylamino, methylamino, ethylamino, phenethylamino, etc.
  • Dialkylamino includes groups wherein the nitrogen of -NH 2 is bound to at least two additional alkyl groups. Examples of dialkylamino groups include, but are not limited to, dimethylamino and diethylamino.
  • Arylamino” and “diarylamino” include groups wherein the nitrogen is bound to at least one or two aryl groups, respectively.
  • Aminoaryl and “aminoaryloxy” refer to aryl and aryloxy substituted with amino.
  • alkylaminoaryl or “arylaminoalkyl” refers to an amino group which is bound to at least one alkyl group and at least one aryl group.
  • Alkaminoalkyl refers to an alkyl, alkenyl, or alkynyl group bound to a nitrogen atom which is also bound to an alkyl group.
  • Acylamino includes groups wherein nitrogen is bound to an acyl group. Examples of acylamino include, but are not limited to, alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido groups.
  • amide or “aminocarboxy” includes compounds or moieties that contain a nitrogen atom that is bound to the carbon of a carbonyl or a thiocarbonyl group.
  • alkaminocarboxy groups that include alkyl, alkenyl or alkynyl groups bound to an amino group which is bound to the carbon of a carbonyl or thiocarbonyl group. It also includes “arylaminocarboxy” groups that include aryl or heteroaryl moieties bound to an amino group that is bound to the carbon of a carbonyl or thiocarbonyl group.
  • alkylaminocarboxy include moieties wherein alkyl, alkenyl, alkynyl and aryl moieties, respectively, are bound to a nitrogen atom which is in turn bound to the carbon of a carbonyl group.
  • Amides can be substituted with substituents such as straight chain alkyl, branched alkyl, cycloalkyl, aryl, heteroaryl or heterocycle. Substituents on amide groups may be further substituted.
  • event(s) may or may not occur, and includes both event(s), which occur, and events that do not occur.
  • pharmaceutically-acceptable salts refers to salts that retain the desired biological activity of the subject compound and exhibit minimal undesired toxicological effects. These pharmaceutically-acceptable salts may be prepared in situ during the final isolation and purification of the compound, or by separately reacting the purified compound in its free acid or free base form with a suitable base or acid, respectively.
  • co-administering and derivatives thereof as used herein is meant either simultaneous administration or any manner of separate sequential administration of one or more additional pharmaceutically active compounds, whether for treating cancer, the side effects of cancer or cancer therapy, or some other disease.
  • additional pharmaceutically active compounds whether for treating cancer, the side effects of cancer or cancer therapy, or some other disease.
  • the compounds are administered in a close time proximity to each other.
  • the compounds are administered in the same dosage form, e.g. one compound may be administered topically and another compound may be administered orally.
  • the compounds of Formulae (I)-(III) include the compounds themselves, as well as their salts, their solvates, their N-oxides, and their prodrugs, if applicable.
  • compounds according to Formulae (I)-(III) may contain an acidic functional group, one acidic enough to form salts.
  • Representative salts include pharmaceutically acceptable metal salts such as sodium, potassium, lithium, calcium, magnesium, aluminum, and zinc salts; carbonates and bicarbonates of a pharmaceutically-acceptable metal salts such as sodium, potassium, lithium, calcium, magnesium, aluminum, and zinc; pharmaceutically-acceptable organic primary, secondary, and tertiary amines including aliphatic amines, aromatic amines, aliphatic diamines, and hydroxy alkylamines such as methylamine, ethylamine, 2-hydroxyethylamine, diethylamine, triethylamine, ethylenediamine, ethanolamine, diethanolamine, and cyclohexylamine.
  • pharmaceutically acceptable metal salts such as sodium, potassium, lithium, calcium, magnesium, aluminum, and zinc salts
  • carbonates and bicarbonates of a pharmaceutically-acceptable metal salts such as sodium, potassium, lithium, calcium, magnesium, aluminum, and zinc
  • pharmaceutically-acceptable organic primary, secondary, and tertiary amines including
  • compounds according to Formulae (I)-(III) may contain a basic functional group and are therefore capable of forming pharmaceutically- acceptable acid addition salts by treatment with a suitable acid.
  • Suitable acids include pharmaceutically- acceptable inorganic acids and pharmaceutically- acceptable organic acids.
  • Representative pharmaceutically acceptable acid addition salts include hydrochloride, hydrobromide, nitrate, methylnitrate, sulfate, bisulfate, sulfamate, phosphate, acetate, hydroxyacetate, phenylacetate, propionate, butyrate, isobutyrate, valerate, maleate, hydroxymaleate, acrylate, fumarate, malate, tartrate, citrate, salicylate, ⁇ -aminosalicylate, glycollate, lactate, heptanoate, phthalate, oxalate, succinate, benzoate, o-acetoxybenzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate,
  • N-oxides can be converted to N-oxides by treatment with an oxidizing agent (e.g. , 3-chloroperoxybenzoic acid (mCPBA) and/or hydrogen peroxides) to afford other compounds of the present invention.
  • an oxidizing agent e.g. , 3-chloroperoxybenzoic acid (mCPBA) and/or hydrogen peroxides
  • mCPBA 3-chloroperoxybenzoic acid
  • hydrogen peroxides hydrogen peroxides
  • all shown and claimed nitrogen-containing compounds are considered, when allowed by valency and structure, to include both the compound as shown and its N-oxide derivative (which can be designated as N— >0 or N + -0 " ).
  • the nitrogens in the compounds of the present invention can be converted to N-hydroxy or N-alkoxy compounds.
  • N-hydroxy compounds can be prepared by oxidation of the parent amine by an oxidizing agent such as m-CPBA.
  • nitrogen-containing compounds are also considered, when allowed by valency and structure, to cover both the compound as shown and its N-hydroxy (i.e. , N-OH) and N-alkoxy (i.e. , N-OR, wherein R is substituted or unsubstituted C -C alkyl, C C 6 alkenyl, C C 6 alkynyl, 3-14-membered carbocycle or 3- 14-membered heterocycle) derivatives.
  • N-OH N-hydroxy
  • N-alkoxy i.e. , N-OR, wherein R is substituted or unsubstituted C -C alkyl, C C 6 alkenyl, C C 6 alkynyl, 3-14-membered carbocycle or 3- 14-membered heterocycle
  • the structural formula of the compound represents a certain isomer for convenience in some cases, but the present invention includes all isomers, such as geometrical isomers, optical isomers based on an asymmetrical carbon, stereoisomers, tautomers, and the like.
  • a crystal polymorphism may be present for the compounds represented by the formula. It is noted that any crystal form, crystal form mixture, or anhydride or hydrate thereof is included in the scope of the present invention. Furthermore, so-called metabolite which is produced by degradation of the present compound in vivo is included in the scope of the present invention.
  • “Isomerism” means compounds that have identical molecular formulae but differ in the sequence of bonding of their atoms or in the arrangement of their atoms in space. Isomers that differ in the arrangement of their atoms in space are termed “stereoisomers.” Stereoisomers that are not mirror images of one another are termed “diastereoisomers,” and stereoisomers that are non-superimposable mirror images of each other are termed “enantiomers” or sometimes optical isomers. A mixture containing equal amounts of individual enantiomeric forms of opposite chirality is termed a "racemic mixture.”
  • a carbon atom bonded to four nonidentical substituents is termed a "chiral center.”
  • Chiral isomer means a compound with at least one chiral center. Compounds with more than one chiral center may exist either as an individual diastereomer or as a mixture of diastereomers, termed "diastereomeric mixture.” When one chiral center is present, a stereoisomer may be characterized by the absolute configuration (R or S) of that chiral center. Absolute configuration refers to the arrangement in space of the substituents attached to the chiral center. The substituents attached to the chiral center under consideration are ranked in accordance with the Sequence Rule of Cahn, Ingold and Prelog. (Cahn et al., Angew. Chem. Inter. Edit.
  • “Geometric isomer” means the diastereomers that owe their existence to hindered rotation about double bonds or a cycloalkyl linker (e.g., 1,3-cylcobutyl). These configurations are differentiated in their names by the prefixes cis and trans, or Z and E, which indicate that the groups are on the same or opposite side of the double bond in the molecule according to the Cahn-Ingold- Prelog rules.
  • atropic isomers are a type of stereoisomer in which the atoms of two isomers are arranged differently in space. Atropic isomers owe their existence to a restricted rotation caused by hindrance of rotation of large groups about a central bond. Such atropic isomers typically exist as a mixture, however as a result of recent advances in chromatography techniques, it has been possible to separate mixtures of two atropic isomers in select cases.
  • Tautomer is one of two or more structural isomers that exist in equilibrium and is readily converted from one isomeric form to another. This conversion results in the formal migration of a hydrogen atom accompanied by a switch of adjacent conjugated double bonds. Tautomers exist as a mixture of a tautomeric set in solution. In solutions where tautomerization is possible, a chemical equilibrium of the tautomers will be reached. The exact ratio of the tautomers depends on several factors, including temperature, solvent and pH. The concept of tautomers that are interconvertable by tautomerizations is called tautomerism.
  • keto-enol tautomerism a simultaneous shift of electrons and a hydrogen atom occurs.
  • Ring-chain tautomerism arises as a result of the aldehyde group (-CHO) in a sugar chain molecule reacting with one of the hydroxy groups (-OH) in the same molecule to give it a cyclic (ring-shaped) form as exhibited by glucose.
  • keto-enol equilibria is between pyridin-2(lH)-ones and the corresponding pyridin-2-ols, as shown below.
  • the compounds of Formulae (I)-(III) may be prepared in crystalline or non-crystalline form, and, if crystalline, may optionally be solvated, e.g., as the hydrate.
  • This invention includes within its scope stoichiometric solvates (e.g., hydrates) as well as compounds containing variable amounts of solvent (e.g., water).
  • Certain of the compounds described herein may contain one or more chiral atoms, or may otherwise be capable of existing as two enantiomers.
  • the compounds claimed below include mixtures of enantiomers as well as purified enantiomers or enantiomerically enriched mixtures.
  • Also included within the scope of the invention are the individual isomers of the compounds represented by Formulae (I)-(III), or claimed below, as well as any wholly or partially equilibrated mixtures thereof.
  • the present invention also covers the individual isomers of the claimed compounds as mixtures with isomers thereof in which one or more chiral centers are inverted.
  • a compound of Formulae (I)-(III), as well as salts, solvates, N-oxides, and the like may be administered as a neat preparation, i.e., no additional carrier, the more usual practice is to present the active ingredient confected with a carrier or diluent.
  • the invention further provides pharmaceutical compositions, which includes a compound of Formulae (I)-(III) and salts, solvates and the like, and one or more pharmaceutically acceptable carriers, diluents, or excipients.
  • the compounds of Formulae (I)- (III) and salts, solvates, N-oxides, etc, are as described above.
  • the carrier(s), diluent, or excipient(s) must be acceptable in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • a process for the preparation of a pharmaceutical formulation including admixing a compound of the Formulae (I)-(III), or salts, solvates, N-oxides, etc, with one or more pharmaceutically acceptable carriers, diluents or excipients.
  • Preferred prodrugs for compounds of the invention include: esters, carbonate esters, hemi-esters, phosphate esters, nitro esters, sulfate esters, sulfoxides, amides, carbamates, azo- compounds, phosphamides, glycosides, ethers, acetals, and ketals.
  • the compounds of the present invention can exist in either hydrated or unhydrated (the anhydrous) form or as solvates with other solvent molecules.
  • hydrates include monohydrates, dihydrates, etc.
  • solvates include ethanol solvates, acetone solvates, etc.
  • Solvate means solvent addition forms that contain either stoichiometric or non stoichiometric amounts of solvent. Some compounds have a tendency to trap a fixed molar ratio of solvent molecules in the crystalline solid state, thus forming a solvate. If the solvent is water the solvate formed is a hydrate; and if the solvent is alcohol, the solvate formed is an alcoholate. Hydrates are formed by the combination of one or more molecules of water with one molecule of the substance in which the water retains its molecular state as H 2 0.
  • analog refers to a chemical compound that is structurally similar to another but differs slightly in composition (as in the replacement of one atom by an atom of a different element or in the presence of a particular functional group, or the replacement of one functional group by another functional group).
  • an analog is a compound that is similar or comparable in function and appearance, but not in structure or origin to the reference compound.
  • the term “derivative” refers to compounds that have a common core structure, and are substituted with various groups as described herein.
  • all of the compounds represented by Formula (I) are aryl- or heteroaryl-substituted benzene compounds, and have Formula (I) as a common core.
  • bioisostere refers to a compound resulting from the exchange of an atom or of a group of atoms with another, broadly similar, atom or group of atoms. The objective of a bioisosteric replacement is to create a new compound with similar biological properties to the parent compound.
  • the bioisosteric replacement may be physicochemically or topologically based. Examples of carboxylic acid bioisosteres include, but are not limited to, acyl
  • the present invention is intended to include all isotopes of atoms occurring in the present compounds.
  • Isotopes include those atoms having the same atomic number but different mass numbers.
  • isotopes of hydrogen include tritium and deuterium
  • isotopes of carbon include C-13 and C-14.
  • Such compounds also include Compound 75
  • the invention further includes a pharmaceutical composition comprising Compound 75
  • An EZH2 antagonist and optionally other therapeutics can be administered per se (neat) or in the form of a pharmaceutically acceptable salt.
  • the salts should be pharmaceutically acceptable, but non-pharmaceutically acceptable salts can conveniently be used to prepare pharmaceutically acceptable salts thereof.
  • compositions useful in accordance with the invention may be provided as salts with pharmaceutically compatible counterions (i.e., pharmaceutically acceptable salts).
  • pharmaceutically compatible counterions i.e., pharmaceutically acceptable salts.
  • “pharmaceutically acceptable salt” means any non-toxic salt that, upon administration to a recipient, is capable of providing, either directly or indirectly, a compound or a prodrug of a compound useful in accordance with this invention.
  • a “pharmaceutically acceptable counterion” is an ionic portion of a salt that is not toxic when released from the salt upon administration to a subject.
  • Pharmaceutically compatible salts may be formed with many acids, including but not limited to hydrochloric, sulfuric, acetic, lactic, tartaric, malic, and succinic acids. Salts tend to be more soluble in water or other protic solvents than their corresponding free base forms. The present invention includes the use of such salts.
  • Pharmaceutically acceptable acid addition salts include those formed with mineral acids such as hydrochloric acid and hydrobromic acid, and also those formed with organic acids such as maleic acid.
  • acids commonly employed to form pharmaceutically acceptable salts include inorganic acids such as hydrogen bisulfide, hydrochloric, hydrobromic, hydroiodic, sulfuric and phosphoric acid, as well as organic acids such as para-toluenesulfonic, salicylic, tartaric, bitartaric, ascorbic, maleic, besylic, fumaric, gluconic, glucuronic, formic, glutamic, methanesulfonic, ethanesulfonic, benzenesulfonic, lactic, oxalic, para-bromophenylsulfonic, carbonic, succinic, citric, benzoic and acetic acid, and related inorganic and organic acids.
  • Such pharmaceutically acceptable salts thus include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caprate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, butyne-l,4-dioate, hexyne-l,6-dioate, benzoate, chlorobenzoate,
  • Suitable bases for forming pharmaceutically acceptable salts with acidic functional groups include, but are not limited to, hydroxides of alkali metals such as sodium, potassium, and lithium; hydroxides of alkaline earth metal such as calcium and magnesium; hydroxides of other metals, such as aluminum and zinc; ammonia, and organic amines, such as unsubstituted or hydroxy- substituted mono-, di-, or trialkylamines; dicyclohexylamine; tributyl amine; pyridine; N-methyl,N-ethylamine; diethylamine; triethylamine; mono-, bis-, or tris-(2-hydroxy-lower alkyl amines), such as mono-, bis-, or tris-(2-hydroxyethyl)amine, 2-hydroxy-tert-butylamine, or tris- (hydroxymethyl)methylamine, N,N-di alkyl-N- (hydroxy alkyl)-amines, such as N,N-dimethyl-N
  • Certain compounds useful in accordance with the invention and their salts may exist in more than one crystalline form (i.e., polymorph); the present invention includes the use of each of the crystal forms and mixtures thereof.
  • Certain compounds useful in accordance with the invention may contain one or more chiral centers, and exist in different optically active forms. When compounds useful in accordance with the invention contain one chiral center, the compounds exist in two
  • enantiomeric forms and the present invention includes the use of both enantiomers and mixtures of enantiomers, such as racemic mixtures thereof.
  • the enantiomers may be resolved by methods known to those skilled in the art; for example, enantiomers may be resolved by formation of diastereoisomeric salts which may be separated, for example, by crystallization; formation of diastereoisomeric derivatives or complexes which may be separated, for example, by
  • a compound useful in accordance with the invention may exist in diastereoisomeric forms.
  • the diastereoisomeric compounds may be separated by methods known to those skilled in the art (for example, chromatography or crystallization) and the individual enantiomers may be separated as described above.
  • the present invention includes the use of various diastereoisomers of compounds useful in
  • Compounds useful in accordance with the invention may exist in different tautomeric forms or as different geometric isomers, and the present invention includes the use of each tautomer and/or geometric isomer of compounds useful in accordance with the invention, and mixtures thereof.
  • Compounds useful in accordance with the invention may exist in zwitterionic form. The present invention includes the use of each zwitterionic form of compounds useful in accordance with the invention, and mixtures thereof.
  • An EZH2 antagonist may, if desired, be presented in a kit (e.g., a pack or dispenser device) which may contain one or more unit dosage forms containing the EZH2 antagonist.
  • the pack may for example comprise metal or plastic foil, such as a blister pack.
  • the pack or dispenser device may be accompanied by instructions for administration.
  • Compositions comprising an EZH2 antagonist of the invention formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition. Instructions for use may also be provided.
  • kits comprising a plurality of methylation detection reagents that detect the methylated H3-K27.
  • the kit includes mono-methylated H3-K27, di- methylated H3-K27 and tri-methylated H3-K27 detection reagents.
  • the detection reagent is for example antibodies or fragments thereof, polypeptide or aptamers.
  • a kit may also include an EZH2 mutant detection reagent, e.g., nucleic acids that specifically identify a mutant EZH2 nucleic acid sequence by having homologous nucleic acid sequences, such as oligonucleotide sequences, complementary to a portion of the mutant EZH2 nucleic acid sequence or antibodies to proteins encoded by the mutant EZH2 nucleic acids packaged together in the form of a kit.
  • the oligonucleotides can be fragments of the EZH2 gene.
  • the oligonucleotides can be 200, 150, 100, 50, 25, 10 or less nucleotides in length.
  • the kit may contain in separate containers an aptamer or an antibody, control formulations (positive and/or negative), and/or a detectable label such as fluorescein, green fluorescent protein, rhodamine, cyanine dyes, Alexa dyes, luciferase, radiolabels, among others.
  • Instructions e.g. , written, tape, VCR, CD-ROM, etc.
  • the assay may for example be in the form of a Western Blot analysis, Immunohistochemistry (IHC), immunofluorescence (IF), sequencing and Mass spectrometry (MS) as known in the art.
  • an element means one element or more than one element.
  • a reference to "A and/or B", when used in conjunction with open-ended language such as “comprising” can refer, in one embodiment, to A only (optionally including elements other than B); in another embodiment, to B only (optionally including elements other than A); in yet another embodiment, to both A and B (optionally including other elements); etc.
  • the phrase "at least one,” in reference to a list of one or more elements, should be understood to mean at least one element selected from any one or more of the elements in the list of elements, but not necessarily including at least one of each and every element specifically listed within the list of elements and not excluding any combinations of elements in the list of elements.
  • This definition also allows that elements may optionally be present other than the elements specifically identified within the list of elements to which the phrase "at least one" refers, whether related or unrelated to those elements specifically identified.
  • At least one of A and B can refer, in one embodiment, to at least one, optionally including more than one, A, with no B present (and optionally including elements other than B); in another embodiment, to at least one, optionally including more than one, B, with no A present (and optionally including elements other than A); in yet another embodiment, to at least one, optionally including more than one, A, and at least one, optionally including more than one, B (and optionally including other elements); etc.
  • co-administration and “co-administering” refer to both concurrent administration (administration of two or more therapeutic agents at the same time) and time varied administration (administration of one or more therapeutic agents at a time different from that of the administration of an additional therapeutic agent or agents), as long as the therapeutic agents are present in the patient to some extent at the same time.
  • precancerous condition or "premalignant condition” refers to a disease, syndrome, or finding that, if left untreated, may lead to cancer. It is a generalized state associated with a significantly increased risk of cancer.
  • treating refers to alleviate of at least one symptom of the disease, disorder or condition.
  • the term encompasses the administration and/or application of one or more compounds described herein, to a subject, for the purpose of providing management of, or remedy for a condition.
  • Treatment for the purposes of this disclosure, may, but does not have to, provide a cure; rather, “treatment” may be in the form of management of the condition.
  • treatment includes partial or total destruction of the undesirable proliferating cells with minimal destructive effects on normal cells.
  • a desired mechanism of treatment of unwanted rapidly proliferating cells, including cancer cells, at the cellular level is apoptosis.
  • preventing includes either preventing or slowing the onset of a clinically evident disease progression altogether or preventing or slowing the onset of a preclinically evident stage of a disease in individuals at risk. This includes prophylactic treatment of those at risk of developing a disease.
  • subject as used herein for purposes of treatment includes any human subject who has been diagnosed with, has symptoms of, or is at risk of developing a cancer or a precancerous condition.
  • subject is any human subject.
  • a subject may be a human subject who is at risk of or is genetically predisposed to obtaining a disorder characterized by unwanted, rapid cell
  • the subject may be at risk due to exposure to carcinogenic agents, being genetically predisposed to disorders characterized by unwanted, rapid cell proliferation, and so on.
  • EZH2 polypeptide encompasses functional fragments of the full-length polypeptides and functional equivalents of either of the foregoing that have substantially similar or substantially identical amino acid sequences (at least about 75%, 80%, 85%, 90%, 95% 98% or more amino acid sequence similarity or identity), where the functional fragment or functional equivalent retains one or more of the functional properties of the native polypeptide.
  • polypeptide or nucleic acid
  • polypeptide has the same or substantially similar activity with respect to one or more of the biological properties of the native polypeptide (or nucleic acid), e.g., at least about 50%, 75%, 85%, 90%, 95% or 98% or more of the activity of the native polypeptide (or nucleic acid).
  • modulate refers to an increase or decrease in activity.
  • the term “increase” or “enhance” means an elevation by at least about 25%, 50%, 75%, 2-fold, 3-fold, 5-fold, 10-fold, 15-fold, 20-fold or more.
  • the terms “decrease” or “reduce” means a diminishment by at least about 25%, 40%, 50%, 60%, 75%, 80%, 85%, 90%, 95%, 98% or more.
  • the indicated activity, substance or other parameter is not detectable. Specifically provided are antagonists of EZH2.
  • pharmacodynamic marker refers to a molecular marker of drug response that can be measured in patients receiving the drug.
  • the marker should be a direct measure of modulation of the drug target and be able to show quantitative changes in response to dose.
  • a potential pharmacodynamic marker for EZH2 antagonists could be levels of histone H3-K27 methylation in disease or surrogate tissue.
  • responsiveness is interchangeable with terms “responsive”, “sensitive”, and “sensitivity”, and it is meant that a subject showing therapeutic response when administered an EZH inhibitor, e.g., tumor cells or tumor tissues of the subject undergo apoptosis and/or necrosis, and/or display reduced growing, dividing, or proliferation.
  • an EZH inhibitor e.g., tumor cells or tumor tissues of the subject undergo apoptosis and/or necrosis, and/or display reduced growing, dividing, or proliferation.
  • control refers to methylation levels ⁇ e.g., monomethylation level, dimethylation level or trimethylation level) detected in an adjacent non-tumor tissue isolated from the subject, detected in a healthy tissue from a healthy subject, or established by a pathologist with standard methods in the art.
  • methylation levels ⁇ e.g., monomethylation level, dimethylation level or trimethylation level
  • sample it means any biological sample derived from the subject, includes but is not limited to, cells, tissues samples and body fluids (including, but not limited to, mucus, blood, plasma, serum, urine, saliva, and semen).
  • compositions are described as having, including, or comprising specific components, it is contemplated that compositions also consist essentially of, or consist of, the recited components.
  • methods or processes are described as having, including, or comprising specific process steps, the processes also consist essentially of, or consist of, the recited processing steps.
  • steps or order for performing certain actions is immaterial so long as the invention remains operable.
  • two or more steps or actions can be conducted simultaneously.
  • the synthetic processes of the invention can tolerate a wide variety of functional groups; therefore various substituted starting materials can be used.
  • the processes generally provide the desired final compound at or near the end of the overall process, although it may be desirable in certain instances to further convert the compound to a pharmaceutically acceptable salt, ester or prodrug thereof.
  • Compounds designed, selected and/or optimized by methods described above, once produced, can be characterized using a variety of assays known to those skilled in the art to determine whether the compounds have biological activity.
  • the molecules can be characterized by conventional assays, including but not limited to those assays described below, to determine whether they have a predicted activity, binding activity and/or binding specificity.
  • high-throughput screening can be used to speed up analysis using such assays.
  • it can be possible to rapidly screen the molecules described herein for activity, using techniques known in the art.
  • General methodologies for performing high- throughput screening are described, for example, in Devlin (1998) High Throughput Screening, Marcel Dekker; and U.S. Patent No. 5,763,263.
  • High-throughput assays can use one or more different assay techniques including, but not limited to, those described below.
  • Wild-type EZH2 (GenBank Accession No. NM_004456) or Tyr641 mutants were co- expressed with wild-type AEBP2 (GenBank Accession No. NM_153207), EED (GenBank Accession No. NM_003797), SUZ12 (GenBank Accession No. NM_015355) and RbAp48 (GenBank Accession No. NM_005610) in Spodoptera frugiperda (Sf9) cells using a baculovirus expression system.
  • An N-terminal FLAG tag on the EED was used to purify active PRC2 complex from cell lysates (BPS Bioscience, catalog number 51004). The purity of the final PRC2 preparations was assessed by SDS-PAGE with Coomassie blue staining.
  • peptides were synthesized representing the amino acid sequence of human H3 from residues 21-44 (H3:21-44) with lysine 27 represented as the unmodified, mono-methylated, di-methylated or tri- methylated side chain amine. These peptides were purchased from New England Peptide (Gardner, MA) with biotin appended to the C-terminus of each peptide.
  • the cell lines OCI-LY19 (ACC 528), KARPAS-422 (ACC 32), and WSU-DLCL2 (ACC 575) were obtained from DSMZ.
  • the cell lines DB (CRL-2289) and SU-DHL6 (CRL-2959) were obtained from ATCC.
  • OCI-LY19, WSU-DLCL2, and DB cell lines were grown in RPMI- 1640 with 10% FBS, and KARPAS-422 and SU-DHL6 cell lines were grown in RPMI-1640 plus 20% FBS.
  • Cells were grown to a density of 1.5-2 xlO 6 cells/mL and 1 x 10 7 cells were harvested by centrifugation at 264 x g, washed in ice cold PBS and lysed by resuspension in a 10X pellet volume of RIPA lysis buffer containing 50 mM Tris-HCl, 15 OmM NaCl, 0.25% DOC, 1% NP-40, and 1 mM EDTA (Millipore #20-188), plus 0.1% SDS and protease inhibitor tablets (Roche # 1836153).
  • Lysates were sonicated by 2 rounds of 10 1-second bursts at setting 3 with a Misonix XL-2000 to ensure efficient histone extraction, and cleared by centrifugation at 4° C using a bench top centrifuge at 14,000 rpm for 10 minutes. Protein concentration was determined by BCA assay (Pierce).
  • membranes were probed with IRDye 800CW donkey-anti-mouse IgG (LiCOR #926-32212) or Alexa Fluor 680 goat-anti-rabbit IgG (Invitrogen #A-21076) secondary Ab and imaged using the LiCOR Odyssey system.
  • heterozygosity was difficult to rationalize as the basis for a malignant phenotype, especially in light of previous data indicating that overexpression of EZH2, loss-of-function mutations in the corresponding H3-K27 demethylase UTX, or overexpression of components of the PRC2, such as PHF19/PCL3, involved in increased H3-K27 trimethylation, all result in malignant phenotypes in specific human cancers. Morin et al. (2010) Nat Genet 42: 181-5; Martinez-Garcia et al. (2010) Nat Genet 42: 100-1; Bracken et al. (2003) EMBO J 22:5323-35; Kleer et al.
  • Recombinant PRC2 complexes were prepared with WT and Tyr641 mutant versions of human EZH2 (see Example 1 above; Cao et al. (2004) Mol Cell 15:57-67). Equal concentrations (nominally 8 nM, based on protein determinations) of each complex were initially tested for the ability to catalyze H-methyl transfer from labeled S-adenosyl methionine (SAM) to an unmodified peptide representing the amino acid sequence surrounding H3-K27 (H3:21-44) or to native avian erythrocyte oligonucleosomes. As previously reported (Morin et al.
  • SAM S-adenosyl methionine
  • the nucleosomes isolated from the avian natural source represent an admixture of states of histone modification, including various states of H3-K27 methylation as judged by Western blotting with H3-K27 methylation- specific antibodies.
  • mutation of Y641 alters the substrate specificity of EZH2 to result in methylation of lysine residues other than H3-K27. This possibility is unlikely given the excellent agreement between mutant activity on small peptide and recombinant H3 protein substrates.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
PCT/US2013/030565 2012-03-12 2013-03-12 Inhibitors of human ezh2, and methods of use thereof WO2013138361A1 (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
ES13711265T ES2718900T3 (es) 2012-03-12 2013-03-12 Inhibidores de EZH2 humana y métodos de uso de los mismos
CN201910052279.0A CN110420327B (zh) 2012-03-12 2013-03-12 人ezh2抑制剂及其应用方法
JP2015500523A JP6321619B2 (ja) 2012-03-12 2013-03-12 ヒトｅｚｈ２の阻害剤およびその使用方法
AU2013232229A AU2013232229B2 (en) 2012-03-12 2013-03-12 Inhibitors of human EZH2, and methods of use thereof
KR1020217018417A KR102453519B1 (ko) 2012-03-12 2013-03-12 인간 ｅｚｈ2의 억제제 및 이의 사용 방법
HK15106526.3A HK1205938B (en) 2012-03-12 2013-03-12 Inhibitors of human ezh2, and methods of use thereof
KR1020227034498A KR102587175B1 (ko) 2012-03-12 2013-03-12 인간 ｅｚｈ2의 억제제 및 이의 사용 방법
CA2867282A CA2867282C (en) 2012-03-12 2013-03-12 Inhibitors of human ezh2, and methods of use thereof
PL13711265T PL2825161T3 (pl) 2012-03-12 2013-03-12 Inhibitory ludzkiej ezh2 i sposoby ich zastosowania
RU2014141045A RU2704445C2 (ru) 2012-03-12 2013-03-12 Ингибиторы ezh2 человека и способы их применения
EP13711265.2A EP2825161B1 (en) 2012-03-12 2013-03-12 Inhibitors of human ezh2, and methods of use thereof
EP18214827.0A EP3536314A1 (en) 2012-03-12 2013-03-12 Inhibitors of human ezh2, and methods of use thereof
CN201380024734.7A CN104540500B (zh) 2012-03-12 2013-03-12 人ezh2抑制剂及其应用方法
KR1020147028560A KR102267502B1 (ko) 2012-03-12 2013-03-12 인간 ｅｚｈ2의 억제제 및 이의 사용 방법
KR1020237033924A KR20230145531A (ko) 2012-03-12 2013-03-12 인간 ｅｚｈ2의 억제제 및 이의 사용 방법
DK13711265.2T DK2825161T3 (en) 2012-03-12 2013-03-12 HUMAN EZH2 INHIBITORS AND PROCEDURES FOR USING IT
AU2018201176A AU2018201176A1 (en) 2012-03-12 2018-02-19 Inhibitors of human ezh2, and methods of use thereof
AU2019250181A AU2019250181A1 (en) 2012-03-12 2019-10-17 Inhibitors of human ezh2, and methods of use thereof
AU2021202119A AU2021202119A1 (en) 2012-03-12 2021-04-07 Inhibitors of human ezh2, and methods of use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/418,242 2012-03-12
US13/418,242 US9175331B2 (en) 2010-09-10 2012-03-12 Inhibitors of human EZH2, and methods of use thereof

Publications (1)

Publication Number Publication Date
WO2013138361A1 true WO2013138361A1 (en) 2013-09-19

Family

ID=47913638

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/030565 WO2013138361A1 (en) 2012-03-12 2013-03-12 Inhibitors of human ezh2, and methods of use thereof

Country Status (14)

Country Link
EP (2) EP2825161B1 (enrdf_load_stackoverflow)
JP (2) JP6321619B2 (enrdf_load_stackoverflow)
KR (4) KR102587175B1 (enrdf_load_stackoverflow)
CN (2) CN110420327B (enrdf_load_stackoverflow)
AU (4) AU2013232229B2 (enrdf_load_stackoverflow)
CA (2) CA3177515A1 (enrdf_load_stackoverflow)
DK (1) DK2825161T3 (enrdf_load_stackoverflow)
ES (1) ES2718900T3 (enrdf_load_stackoverflow)
HU (1) HUE042271T2 (enrdf_load_stackoverflow)
PL (1) PL2825161T3 (enrdf_load_stackoverflow)
PT (1) PT2825161T (enrdf_load_stackoverflow)
RU (2) RU2704445C2 (enrdf_load_stackoverflow)
TR (1) TR201904660T4 (enrdf_load_stackoverflow)
WO (1) WO2013138361A1 (enrdf_load_stackoverflow)

Cited By (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014062732A1 (en) * 2012-10-15 2014-04-24 Epizyme, Inc. Substituted benzene compounds
WO2014062720A3 (en) * 2012-10-15 2014-06-19 Epizyme, Inc. Methods of treating cancer
WO2015058125A1 (en) * 2013-10-18 2015-04-23 Epizyme, Inc. Method of treating cancer
US9051269B2 (en) 2011-11-18 2015-06-09 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
JP2015518001A (ja) * 2012-04-13 2015-06-25 エピザイム，インコーポレイティド がんを処置するための組合せ治療
US9085583B2 (en) 2012-02-10 2015-07-21 Constellation—Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US9090562B2 (en) 2011-04-13 2015-07-28 Epizyme, Inc. Aryl- or heteroaryl-substituted benzene compounds
WO2015128837A1 (en) * 2014-02-26 2015-09-03 Glaxosmithkline Intellectual Property (No.2) Limited Methods of treating cancer patients responding to ezh2 inhibitor gsk126
JP2015531366A (ja) * 2012-09-28 2015-11-02 ファイザー・インク ベンズアミドおよびヘテロベンズアミド化合物
WO2015196064A1 (en) 2014-06-19 2015-12-23 Memorial Sloan-Kettering Cancer Center Biomarkers for response to ezh2 inhibitors
WO2015195848A1 (en) * 2014-06-17 2015-12-23 Epizyme, Inc. Ezh2 inhibitors for treating lymphoma
WO2016061507A1 (en) * 2014-10-16 2016-04-21 Epizyme, Inc. Method for treating cancer
WO2016081523A1 (en) * 2014-11-17 2016-05-26 Epizyme, Inc. Method for treating cancer
WO2016172332A1 (en) * 2015-04-22 2016-10-27 The University Of North Carolina At Chapel Hill A novel compound for the treatment of ewing sarcoma and high-throughput assays for identifying small molecules that modulate aberrant chromatin accessibility
WO2017079738A1 (en) * 2015-11-05 2017-05-11 Epizyme, Inc. Flow cytometry for monitoring histone h3 methylation status
US9718838B2 (en) 2015-08-27 2017-08-01 Eli Lilly And Company Inhibitors of EZH2
US9745305B2 (en) 2013-03-15 2017-08-29 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2017201585A1 (en) * 2016-05-26 2017-11-30 Genea Ip Holdings Pty Ltd Modulators of dux4 for regulation of muscle function
US9969716B2 (en) 2013-08-15 2018-05-15 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
US10040782B2 (en) 2013-10-16 2018-08-07 Epizyme, Inc. Hydrochloride salt form for EZH2 inhibition
CN109069508A (zh) * 2016-04-22 2018-12-21 达纳-法伯癌症研究所股份有限公司 Ezh2抑制剂及其用途
US10220036B2 (en) 2014-12-23 2019-03-05 Novartis Ag Triazolopyrimidine compounds and uses thereof
US10245269B2 (en) 2012-04-13 2019-04-02 Epizyme, Inc. Salt form of a human histone methyltransferase EZH2 inhibitor
US10258628B2 (en) 2016-10-26 2019-04-16 Genea Biocells USA (Holdings), Inc. Generation of muscle lineage cells and therapeutic uses thereof
US10457640B2 (en) 2016-10-19 2019-10-29 Constellation Pharmaceuticals, Inc. Synthesis of inhibitors of EZH2
US10463671B2 (en) 2013-12-06 2019-11-05 Epizyme, Inc. Combination therapy for treating cancer
US10493076B2 (en) 2015-08-24 2019-12-03 Epizyme, Inc. Method for treating cancer
US10577350B2 (en) 2015-08-28 2020-03-03 Constellation Pharmaceuticals, Inc. Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide
US10676479B2 (en) 2016-06-20 2020-06-09 Novartis Ag Imidazolepyridine compounds and uses thereof
US10689378B2 (en) 2016-06-20 2020-06-23 Novartis Ag Triazolopyridine compounds and uses thereof
US11091489B2 (en) 2016-06-20 2021-08-17 Novartis Ag Crystalline forms of a triazolopyrimidine compound
EP3885343A1 (en) 2014-11-06 2021-09-29 Dana-Farber Cancer Institute, Inc. Indole compounds as ezh2 inhibitors and uses thereof
US11147819B2 (en) 2016-06-17 2021-10-19 Epizyme, Inc. EZH2 inhibitors for treating cancer
US11173160B2 (en) 2019-04-22 2021-11-16 University of Pittsburgh—of the Commonwealth System of Higher Education Use of TG02 for treating gliomas in pediatric subjects
US11202781B2 (en) 2015-06-10 2021-12-21 Epizyme, Inc. EZH2 inhibitors for treating lymphoma
US11326212B2 (en) 2010-06-23 2022-05-10 British Columbia Cancer Agency Branch Biomarkers for non-hodgkin lymphomas and uses thereof
US11452727B2 (en) 2017-09-05 2022-09-27 Epizyme, Inc. Combination therapy for treating cancer
WO2023025856A1 (en) 2021-08-25 2023-03-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of ezh2 inhibitors for the treatment of aortic valve stenosis
US11602529B2 (en) 2017-06-02 2023-03-14 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
US11642346B2 (en) 2017-03-31 2023-05-09 Epizyme, Inc. Combination therapy for treating cancer
US11786533B2 (en) 2016-06-01 2023-10-17 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
US12043630B2 (en) 2017-08-18 2024-07-23 Cothera Bioscience, Inc. Polymorphic form of TG02 for treating cancer
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2999898A1 (en) * 2015-09-25 2017-03-30 Epizyme, Inc. Method of treating malignant rhabdoid tumor of the ovary (mrto)/small cell cancer of the ovary of the hypercalcemic type (sccoht) with an ezh2 inhibitor
CN108699029B (zh) * 2016-11-11 2021-07-30 上海海雁医药科技有限公司 4,5,6-三取代吲唑类衍生物、其制法与医药上的用途
CN106963765B (zh) * 2017-03-28 2020-04-07 上海交通大学医学院附属第九人民医院 Ezh2抑制剂化合物在制备治疗眼部黑色素瘤的药物中的应用
WO2019204998A1 (zh) * 2018-04-25 2019-10-31 北京肿瘤医院 Ezh2抑制剂在治疗粘膜型黑色素瘤中的应用
ES2941777T3 (es) * 2018-06-03 2023-05-25 Chen Wen Pin Método para el tratamiento de la cardiomiopatía no compactada
CN111683936B (zh) * 2018-07-27 2021-08-20 苏州信诺维医药科技股份有限公司 多取代苯环化合物、制备方法及其用途
CN110960525A (zh) * 2019-11-26 2020-04-07 济南大学 新型eed-ezh2相互作用抑制剂的确定和评价
CN113024516B (zh) * 2021-03-29 2022-05-17 中国药科大学 双靶点parp/ezh2抑制剂、制备方法及用途
CN119143880A (zh) * 2024-09-20 2024-12-17 上海交通大学医学院附属第九人民医院 抗ezh2蛋白抗体及其应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
US7563589B2 (en) 2004-06-01 2009-07-21 The University Of North Carolina At Chapel Hill Reconstituted histone methyltransferase complex and methods of identifying modulators thereof
WO2011140325A1 (en) 2010-05-07 2011-11-10 Glaxosmithkline Llc Indazoles
WO2011140324A1 (en) 2010-05-07 2011-11-10 Glaxosmithkline Llc Indoles
WO2012005805A1 (en) 2010-05-07 2012-01-12 Glaxosmithkline Llc Azaindazoles
WO2012034132A2 (en) * 2010-09-10 2012-03-15 Epizyme, Inc. Inhibitors of human ezh2, and methods of use thereof
WO2013049770A2 (en) * 2011-09-30 2013-04-04 Glaxosmithkline Llc Methods of treating cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700293B2 (en) * 2001-08-02 2010-04-20 The Regents Of The University Of Michigan Expression profile of prostate cancer
ES2324435B1 (es) * 2005-10-27 2010-05-31 Fundacion Para El Estudio De La Hematologia Y Hemoterapia De Aragon (Fehha) Procedimiento y dispositivo de analisis in vitro de mrna de genes implicados en neoplasias hematologicas.
WO2008101118A2 (en) * 2007-02-14 2008-08-21 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services A gene expression signature identifying pro-angiogenic genes in ovarian tumor endothelial cell isolates
US20090012031A1 (en) 2007-07-03 2009-01-08 The Regents Of The University Of Michigan EZH2 Cancer Markers
WO2009124137A2 (en) * 2008-04-01 2009-10-08 Mount Sinai School Of Medicine Of New York University Method of suppressing gene transcription through histone lysine methylation
JO3438B1 (ar) * 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
US7563589B2 (en) 2004-06-01 2009-07-21 The University Of North Carolina At Chapel Hill Reconstituted histone methyltransferase complex and methods of identifying modulators thereof
WO2011140325A1 (en) 2010-05-07 2011-11-10 Glaxosmithkline Llc Indazoles
WO2011140324A1 (en) 2010-05-07 2011-11-10 Glaxosmithkline Llc Indoles
WO2012005805A1 (en) 2010-05-07 2012-01-12 Glaxosmithkline Llc Azaindazoles
WO2012034132A2 (en) * 2010-09-10 2012-03-15 Epizyme, Inc. Inhibitors of human ezh2, and methods of use thereof
WO2013049770A2 (en) * 2011-09-30 2013-04-04 Glaxosmithkline Llc Methods of treating cancer

Non-Patent Citations (61)

* Cited by examiner, † Cited by third party
Title
"Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide to Medicinal Chemists and Pharmacologists", 2005, WILEY
"Remington's ''The Science and Practice of Pharmacy" 21st ed.,", 2005, LIPPINCOTT WILLIAMS & WILKINS
BARSKI, CELL, vol. 129, 2007, pages 823 - 37
BEISEL ET AL., NATURE, vol. 419, 2002, pages 857 - 62
BENTLEY, CURR OPIN GENET DEV., vol. 16, 2006, pages 545 - 52
BERNSTEIN ET AL., CELL, vol. 125, 2006, pages 315 - 26
BRACKEN ET AL., EMBO J, vol. 22, 2003, pages 5323 - 35
CAHN ET AL., ANGEW. CHEM. INTER. EDIT., vol. 5, 1966, pages 385
CAHN ET AL., ANGEW. CHEM., vol. 78, 1966, pages 413
CAHN ET AL., EXPERIENTIA, vol. 12, 1956, pages 81
CAHN, J. CHEM. EDUC., vol. 41, 1964, pages 116
CAHN; INGOLD, J. CHEM. SOC., 1951, pages 612
CAO ET AL., MOL CELL BIOL, vol. 28, 2008, pages 1862 - 72
CAO ET AL., MOL CELL, vol. 15, 2004, pages 57 - 67
CAO ET AL., SCIENCE, vol. 298, 2002, pages 1039 - 43
CHEN ET AL., GENOMICS, vol. 38, 1996, pages 30 - 7
CHRISTINA R. MAJER ET AL: "A687V EZH2 is a gain-of-function mutation found in lymphoma patients", FEBS LETTERS, vol. 586, no. 19, 28 July 2012 (2012-07-28), pages 3448 - 3451, XP055075954, ISSN: 0014-5793, DOI: 10.1016/j.febslet.2012.07.066 *
COPELAND ET AL., CURR OPIN CHEM BIOL, vol. 14, no. 4, 2010, pages 505 - 10
COPELAND ET AL., NAT REV DRUG DISCOV, vol. 8, 2009, pages 724 - 32
COPELAND, R. A.: "Mechanism and Data Analysis", 2000, WILEY, article "Enzymes: A Practical Introduction to Structure"
CUI ET AL., CELL STEM CELL, vol. 4, 2009, pages 80 - 93
CZERMIN ET AL., CELL, vol. 111, 2002, pages 185 - 96
D. B. YAP ET AL: "Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation", BLOOD, vol. 117, no. 8, 29 December 2010 (2010-12-29), pages 2451 - 2459, XP055075957, ISSN: 0006-4971, DOI: 10.1182/blood-2010-11-321208 *
DEVLIN: "High Throughput Screening", 1998, MARCEL DEKKER
ERHARDT ET AL., DEVELOPMENT, vol. 130, 2003, pages 4235 - 48
F. M. AUSUBEL, ET AL.: "Current Protocols in Molecular Biology", JOHN WILEY & SONS, INC.
F.M. AUSUBEL ET AL.: "Current Protocols in Molecular Biology", GREEN PUBLISHING ASSOCIATES, INC.
FANG ET AL., METHODS ENZYMOL, vol. 377, 2004, pages 213 - 26
FRANCIS ET AL., NAT REV MOL CELL BIOL, vol. 2, 2001, pages 409 - 21
GREENE, T.W.; WUTS, P.G. M.: "Protective Groups in Organic Synthesis, 3rd edition,", 1999, JOHN WILEY & SONS
J. SAMBROOK, ET AL.,: "Molecular Cloning: A Laboratory Manual, Second Edition,", 1989, COLD SPRING HARBOR LABORATORY PRESS
KIRMIZIS ET AL., GENES DEV, vol. 18, 2007, pages 1592 - 1605
KIRMIZIS ET AL., MOL CANCER THER, vol. 2, 2003, pages 113 - 21
KLEER ET AL., PROC NATL ACAD SCI USA, vol. 100, 2003, pages 11606 - 11
KOHLER; MILSTEIN, NATURE, vol. 256, no. 5517, 1975, pages 495 - 7
KUZMICHEV ET AL., GENES DEV, vol. 16, 2002, pages 2893 - 905
LI ET AL., GENOME RES, vol. 19, 2009, pages 1124 - 32
M. T. MCCABE ET AL: "Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 109, no. 8, 21 February 2012 (2012-02-21), pages 2989 - 2994, XP055075955, ISSN: 0027-8424, DOI: 10.1073/pnas.1116418109 *
MARTINEZ-GARCIA ET AL., NAT GENET, vol. 42, 2010, pages 100 - 1
MILNE ET AL., MOL CELL, vol. 10, 2002, pages 1107 - 17
MORIN ET AL., NAT GENET, vol. 42, 2010, pages 181 - 5
MORIN ET AL., NAT GENET, vol. 42, no. 2, 2010, pages 181 - 5
MULLER ET AL., CELL, vol. 111, 2002, pages 197 - 208
NAKAMURA ET AL., MOL CELL, vol. 10, 2002, pages 1119 - 28
OTTE ET AL., CURR OPIN GENET DEV, vol. 13, 2003, pages 448 - 54
PATANI; LAVOIE, CHEM. REV., vol. 96, 1996, pages 3147 - 3176
PLATH ET AL., SCIENCE, vol. 300, 2003, pages 131 - 5
POLLOCK ET AL., DRUG DISCOVERY TODAY: THERAPEUTIC STRATEGIES, vol. 6, no. 1, 2010, pages 71 - 9
RUSSELL J. H. RYAN ET AL: "EZH2 Codon 641 Mutations are Common in BCL2-Rearranged Germinal Center B Cell Lymphomas", PLOS ONE, vol. 6, no. 12, 14 December 2011 (2011-12-14), pages e28585, XP055075962, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0028585 *
SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual, 3rd Ed.", 2001, COLD SPRING HARBOR, N.Y.
SARMA ET AL., MOL CELL BIOL, vol. 28, 2008, pages 2718 - 31
SHEN, X. ET AL., MOL CELL, vol. 32, 2008, pages 491 - 502
SILVA ET AL., DEV CELL, vol. 4, 2003, pages 481 - 95
SIMON ET AL., CURR OPIN GENET DEV, vol. 12, 2002, pages 210 - 8
SIMON ET AL., MUTAT RES, vol. 647, 2008, pages 21 - 9
SMITH, M. B.; MARCH, J.: "March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 5th edition,", 2001, JOHN WILEY & SONS
TIM J WIGLE ET AL: "The Y641C mutation of EZH2 alters substrate specificity for histone H3 lysine 27 methylation states", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 585, no. 19, 17 August 2011 (2011-08-17), pages 3011 - 3014, XP028300045, ISSN: 0014-5793, [retrieved on 20110817], DOI: 10.1016/J.FEBSLET.2011.08.018 *
TOWNSEND, A. P. ET AL., ORG. LET., vol. 11, 2009, pages 2976 - 2979
VAN HAAFTEN ET AL., NAT GENET, vol. 41, 2009, pages 521 - 3
VARAMBALLY ET AL., NATURE, vol. 419, 2002, pages 624 - 9
WANG ET AL., GENE, vol. 343, 2004, pages 69 - 78

Cited By (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11326212B2 (en) 2010-06-23 2022-05-10 British Columbia Cancer Agency Branch Biomarkers for non-hodgkin lymphomas and uses thereof
US9522152B2 (en) 2011-04-13 2016-12-20 Epizyme, Inc. Aryl- or heteroaryl-substituted benzene compounds
US9855275B2 (en) 2011-04-13 2018-01-02 Epizyme, Inc. Aryl-or heteroaryl-substituted benzene compounds
US10420775B2 (en) 2011-04-13 2019-09-24 Epizyme, Inc. Aryl-or heteroaryl-substituted benzene compounds
US9549931B2 (en) 2011-04-13 2017-01-24 Epizyme, Inc. Aryl- or heteroaryl-substituted benzene compounds
US12168016B2 (en) 2011-04-13 2024-12-17 Epizyme, Inc. Aryl-OR heteroaryl-substituted benzene compounds
US10155002B2 (en) 2011-04-13 2018-12-18 Epizyme, Inc. Aryl- or heteroaryl-substituted benzene compounds
US9090562B2 (en) 2011-04-13 2015-07-28 Epizyme, Inc. Aryl- or heteroaryl-substituted benzene compounds
US12161645B2 (en) 2011-04-13 2024-12-10 Epizyme, Inc. Aryl-or heteroaryl-substituted benzene compounds
US11052093B2 (en) 2011-04-13 2021-07-06 Epizyme, Inc. Aryl-or heteroaryl-substituted benzene compounds
US12168015B2 (en) 2011-04-13 2024-12-17 Epizyme, Inc. Aryl-or heteroaryl-substituted benzene compounds
US9051269B2 (en) 2011-11-18 2015-06-09 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US9409865B2 (en) 2011-11-18 2016-08-09 Constellation_Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US9085583B2 (en) 2012-02-10 2015-07-21 Constellation—Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US9980952B2 (en) 2012-02-10 2018-05-29 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
USRE47428E1 (en) 2012-02-10 2019-06-11 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US10016405B2 (en) 2012-02-10 2018-07-10 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US9469646B2 (en) 2012-02-10 2016-10-18 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US9371331B2 (en) 2012-02-10 2016-06-21 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US10245269B2 (en) 2012-04-13 2019-04-02 Epizyme, Inc. Salt form of a human histone methyltransferase EZH2 inhibitor
US10821113B2 (en) 2012-04-13 2020-11-03 Epizyme, Inc. Salt form of a human histone methyltransferase EZH2 inhibitor
EP4140487A1 (en) * 2012-04-13 2023-03-01 Epizyme Inc Combination therapy for treating cancer
JP2015518001A (ja) * 2012-04-13 2015-06-25 エピザイム，インコーポレイティド がんを処置するための組合せ治療
US10787440B2 (en) 2012-04-13 2020-09-29 Epizyme, Inc. Combination therapy for treating cancer
JP2023099080A (ja) * 2012-04-13 2023-07-11 エピザイム，インコーポレイティド がんを処置するための組合せ治療
US12251386B2 (en) 2012-04-13 2025-03-18 Epizyme, Inc. Salt form of a human histone methyltransferase EZH2 inhibitor
US10301290B2 (en) 2012-04-13 2019-05-28 Epizyme, Inc. Combination therapy for treating cancer
EP2836216A4 (en) * 2012-04-13 2015-12-09 Epizyme Inc COMBINATION THERAPY FOR THE TREATMENT OF CANCER
US11370781B2 (en) 2012-04-13 2022-06-28 Epizyme, Inc. Combination therapy for treating cancer
US11491163B2 (en) 2012-04-13 2022-11-08 Epizyme, Inc. Salt form of a human histone methyltransferase EZH2 inhibitor
JP2015531366A (ja) * 2012-09-28 2015-11-02 ファイザー・インク ベンズアミドおよびヘテロベンズアミド化合物
US11642348B2 (en) 2012-10-15 2023-05-09 Epizyme, Inc. Substituted benzene compounds
US9006242B2 (en) 2012-10-15 2015-04-14 Epizyme, Inc. Substituted benzene compounds
WO2014062732A1 (en) * 2012-10-15 2014-04-24 Epizyme, Inc. Substituted benzene compounds
EP3659606A1 (en) * 2012-10-15 2020-06-03 Epizyme, Inc. Methods of treating cancer
US9688665B2 (en) 2012-10-15 2017-06-27 Epizyme, Inc. Methods of treating cancer
AU2013331381B2 (en) * 2012-10-15 2018-04-05 Epizyme, Inc. Substituted benzene compounds
WO2014062733A3 (en) * 2012-10-15 2014-06-12 Epizyme, Inc. Substituted benzene compounds
CN110041250A (zh) * 2012-10-15 2019-07-23 Epizyme股份有限公司 经取代的苯化合物
US9532992B2 (en) 2012-10-15 2017-01-03 Epizyme, Inc. Substituted benzene compounds
WO2014062720A3 (en) * 2012-10-15 2014-06-19 Epizyme, Inc. Methods of treating cancer
US10092572B2 (en) 2012-10-15 2018-10-09 Epizyme, Inc. Substituted benzene compounds
US10098888B2 (en) 2012-10-15 2018-10-16 Epizyme, Inc. Substituted benzene compounds
US12162865B2 (en) 2012-10-15 2024-12-10 Epizyme, Inc. Methods of treating cancer
US20150284370A1 (en) * 2012-10-15 2015-10-08 Epizyme, Inc. Substituted benzene compounds
US9089575B2 (en) 2012-10-15 2015-07-28 Epizyme, Inc. Substituted benzene compounds
CN105102432B (zh) * 2012-10-15 2019-01-04 Epizyme股份有限公司 经取代的苯化合物
EP3725314A1 (en) * 2012-10-15 2020-10-21 Epizyme, Inc. Substituted benzene compounds
US9745305B2 (en) 2013-03-15 2017-08-29 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US9969716B2 (en) 2013-08-15 2018-05-15 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
US10040782B2 (en) 2013-10-16 2018-08-07 Epizyme, Inc. Hydrochloride salt form for EZH2 inhibition
US10710987B2 (en) 2013-10-16 2020-07-14 Epizyme, Inc. Hydrochloride salt form for EZH2 inhibition
WO2015058125A1 (en) * 2013-10-18 2015-04-23 Epizyme, Inc. Method of treating cancer
EP3057594A4 (en) * 2013-10-18 2017-06-07 Epizyme, Inc. Method of treating cancer
US10463671B2 (en) 2013-12-06 2019-11-05 Epizyme, Inc. Combination therapy for treating cancer
WO2015128837A1 (en) * 2014-02-26 2015-09-03 Glaxosmithkline Intellectual Property (No.2) Limited Methods of treating cancer patients responding to ezh2 inhibitor gsk126
CN106999498A (zh) * 2014-06-17 2017-08-01 Epizyme股份有限公司 用于治疗淋巴瘤的ezh2抑制剂
EA038337B1 (ru) * 2014-06-17 2021-08-11 Эпизим, Инк. Ингибиторы ezh2 для лечения лимфомы
WO2015195848A1 (en) * 2014-06-17 2015-12-23 Epizyme, Inc. Ezh2 inhibitors for treating lymphoma
CN106999498B (zh) * 2014-06-17 2021-06-08 Epizyme股份有限公司 用于治疗淋巴瘤的ezh2抑制剂
US11642347B2 (en) 2014-06-17 2023-05-09 Epizyme, Inc. EZH2 inhibitors for treating lymphoma
CN113289022A (zh) * 2014-06-17 2021-08-24 Epizyme股份有限公司 用于治疗淋巴瘤的ezh2抑制剂
US10166238B2 (en) 2014-06-17 2019-01-01 Epizyme, Inc. EZH2 inhibitors for treating lymphoma
AU2020244382B2 (en) * 2014-06-17 2022-08-04 Epizyme, Inc. Ezh2 inhibitors for treating lymphoma
WO2015196064A1 (en) 2014-06-19 2015-12-23 Memorial Sloan-Kettering Cancer Center Biomarkers for response to ezh2 inhibitors
US10369155B2 (en) 2014-10-16 2019-08-06 Epizyme, Inc. Method for treating cancer
AU2021200995B2 (en) * 2014-10-16 2022-06-02 Epizyme, Inc. Method for treating cancer
US9889138B2 (en) 2014-10-16 2018-02-13 Epizyme, Inc. Method for treating cancer
IL276545A (en) * 2014-10-16 2020-09-30 Epizyme Inc Method for treating cancer
JP2020097615A (ja) * 2014-10-16 2020-06-25 エピザイム，インコーポレイティド 癌を治療する方法
US10946024B2 (en) 2014-10-16 2021-03-16 Epizyme, Inc. Method for treating cancer
JP2017532338A (ja) * 2014-10-16 2017-11-02 エピザイム，インコーポレイティド 癌を治療する方法
WO2016061507A1 (en) * 2014-10-16 2016-04-21 Epizyme, Inc. Method for treating cancer
US11236082B2 (en) 2014-11-06 2022-02-01 Dana-Farber Cancer Institute, Inc. EZH2 inhibitors and uses thereof
EP3885343A1 (en) 2014-11-06 2021-09-29 Dana-Farber Cancer Institute, Inc. Indole compounds as ezh2 inhibitors and uses thereof
AU2015350108B2 (en) * 2014-11-17 2021-04-08 Eisai R&D Management Co., Ltd. Method for treating cancer
US10786511B2 (en) 2014-11-17 2020-09-29 Epizyme, Inc. Method for treating cancer
KR102644844B1 (ko) 2014-11-17 2024-03-07 에피자임, 인코포레이티드 암을 치료하기 위한 방법
AU2021204706B2 (en) * 2014-11-17 2023-11-23 Eisai R&D Management Co., Ltd. Method for treating cancer
WO2016081523A1 (en) * 2014-11-17 2016-05-26 Epizyme, Inc. Method for treating cancer
US12168014B2 (en) 2014-11-17 2024-12-17 Epizyme, Inc. Method for treating cancer
KR102338802B1 (ko) 2014-11-17 2021-12-14 에피자임, 인코포레이티드 암을 치료하기 위한 방법
KR20210156840A (ko) * 2014-11-17 2021-12-27 에피자임, 인코포레이티드 암을 치료하기 위한 방법
KR20170103768A (ko) * 2014-11-17 2017-09-13 에피자임, 인코포레이티드 암을 치료하기 위한 방법
US11931363B2 (en) 2014-12-23 2024-03-19 Novartis Ag Triazolopyrimidine compounds and uses thereof
US10220036B2 (en) 2014-12-23 2019-03-05 Novartis Ag Triazolopyrimidine compounds and uses thereof
WO2016172332A1 (en) * 2015-04-22 2016-10-27 The University Of North Carolina At Chapel Hill A novel compound for the treatment of ewing sarcoma and high-throughput assays for identifying small molecules that modulate aberrant chromatin accessibility
US11202781B2 (en) 2015-06-10 2021-12-21 Epizyme, Inc. EZH2 inhibitors for treating lymphoma
US11951109B2 (en) 2015-06-10 2024-04-09 Epizyme, Inc. EZH2 inhibitors for treating lymphoma
US10493076B2 (en) 2015-08-24 2019-12-03 Epizyme, Inc. Method for treating cancer
US10898490B2 (en) 2015-08-24 2021-01-26 Epizyme, Inc. Method for treating cancer
US11642349B2 (en) 2015-08-24 2023-05-09 Epizyme, Inc. Method for treating cancer
US9718838B2 (en) 2015-08-27 2017-08-01 Eli Lilly And Company Inhibitors of EZH2
US10577350B2 (en) 2015-08-28 2020-03-03 Constellation Pharmaceuticals, Inc. Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide
WO2017079738A1 (en) * 2015-11-05 2017-05-11 Epizyme, Inc. Flow cytometry for monitoring histone h3 methylation status
EP3674709A1 (en) 2015-11-05 2020-07-01 Epizyme Inc Flow cytometry for monitoring histone h3 methylation status
CN109069508A (zh) * 2016-04-22 2018-12-21 达纳-法伯癌症研究所股份有限公司 Ezh2抑制剂及其用途
US10633371B2 (en) * 2016-04-22 2020-04-28 Dana-Farber Cancer Institute, Inc. EZH2 inhibitors and uses thereof
WO2017201585A1 (en) * 2016-05-26 2017-11-30 Genea Ip Holdings Pty Ltd Modulators of dux4 for regulation of muscle function
US11786533B2 (en) 2016-06-01 2023-10-17 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
US11147819B2 (en) 2016-06-17 2021-10-19 Epizyme, Inc. EZH2 inhibitors for treating cancer
US10676479B2 (en) 2016-06-20 2020-06-09 Novartis Ag Imidazolepyridine compounds and uses thereof
US11548897B2 (en) 2016-06-20 2023-01-10 Novartis Ag Crystalline forms of a triazolopyrimidine compound
US10689378B2 (en) 2016-06-20 2020-06-23 Novartis Ag Triazolopyridine compounds and uses thereof
US11091489B2 (en) 2016-06-20 2021-08-17 Novartis Ag Crystalline forms of a triazolopyrimidine compound
US10457640B2 (en) 2016-10-19 2019-10-29 Constellation Pharmaceuticals, Inc. Synthesis of inhibitors of EZH2
US10258628B2 (en) 2016-10-26 2019-04-16 Genea Biocells USA (Holdings), Inc. Generation of muscle lineage cells and therapeutic uses thereof
US11642346B2 (en) 2017-03-31 2023-05-09 Epizyme, Inc. Combination therapy for treating cancer
US11602529B2 (en) 2017-06-02 2023-03-14 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
US12043630B2 (en) 2017-08-18 2024-07-23 Cothera Bioscience, Inc. Polymorphic form of TG02 for treating cancer
US11452727B2 (en) 2017-09-05 2022-09-27 Epizyme, Inc. Combination therapy for treating cancer
US11173160B2 (en) 2019-04-22 2021-11-16 University of Pittsburgh—of the Commonwealth System of Higher Education Use of TG02 for treating gliomas in pediatric subjects
WO2023025856A1 (en) 2021-08-25 2023-03-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of ezh2 inhibitors for the treatment of aortic valve stenosis
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors

Also Published As

Publication number Publication date
AU2021202119A1 (en) 2021-05-06
AU2013232229B2 (en) 2017-11-23
RU2704445C2 (ru) 2019-10-28
CA2867282C (en) 2024-04-02
CN104540500A (zh) 2015-04-22
EP2825161B1 (en) 2019-01-02
KR20140147836A (ko) 2014-12-30
PL2825161T3 (pl) 2019-06-28
KR20220139453A (ko) 2022-10-14
HUE042271T2 (hu) 2019-06-28
RU2014141045A (ru) 2016-05-10
RU2019132222A (ru) 2021-06-03
CA3177515A1 (en) 2013-09-19
KR102587175B1 (ko) 2023-10-06
DK2825161T3 (en) 2019-04-08
PT2825161T (pt) 2019-04-29
JP6321619B2 (ja) 2018-05-09
CN110420327B (zh) 2022-05-03
HK1205938A1 (en) 2015-12-31
JP2018083821A (ja) 2018-05-31
JP6592071B2 (ja) 2019-10-16
AU2019250181A1 (en) 2019-11-07
ES2718900T3 (es) 2019-07-05
CN110420327A (zh) 2019-11-08
KR20230145531A (ko) 2023-10-17
CN104540500B (zh) 2019-02-22
KR20210079384A (ko) 2021-06-29
TR201904660T4 (tr) 2019-05-21
AU2018201176A1 (en) 2018-03-08
KR102267502B1 (ko) 2021-06-24
EP2825161A1 (en) 2015-01-21
AU2013232229A1 (en) 2014-10-02
EP3536314A1 (en) 2019-09-11
JP2015511603A (ja) 2015-04-20
KR102453519B1 (ko) 2022-10-11
CA2867282A1 (en) 2013-09-19

Similar Documents

Publication Publication Date Title
JP6592071B2 (ja) ヒトｅｚｈ２の阻害剤およびその使用方法
US20200016162A1 (en) Inhibitors of human ezh2, and methods of use thereof
JP2021169450A (ja) ヒトｅｚｈ２の阻害剤、およびその使用方法
HK40014372A (en) Inhibitors of human ezh2, and methods of use thereof
HK1205938B (en) Inhibitors of human ezh2, and methods of use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13711265

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2015500523

Country of ref document: JP

Kind code of ref document: A

Ref document number: 2867282

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2013232229

Country of ref document: AU

Date of ref document: 20130312

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20147028560

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2013711265

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2014141045

Country of ref document: RU

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014022715

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112014022715

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20140912